
<html lang="en"     class="pb-page"  data-request-id="b6c94db9-35c2-4d17-a6ab-b70ec504da5a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-24;requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.0c01684;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment" /></meta><meta name="dc.Creator" content="Binbin  Cheng" /></meta><meta name="dc.Creator" content="Wei  Wang" /></meta><meta name="dc.Creator" content="Xiaoge  Niu" /></meta><meta name="dc.Creator" content="Yichang  Ren" /></meta><meta name="dc.Creator" content="Ting  Liu" /></meta><meta name="dc.Creator" content="Hao  Cao" /></meta><meta name="dc.Creator" content="Shuanghu  Wang" /></meta><meta name="dc.Creator" content="Yingfeng  Tu" /></meta><meta name="dc.Creator" content="Jingxuan  Chen" /></meta><meta name="dc.Creator" content="Shuwen  Liu" /></meta><meta name="dc.Creator" content="Xuchao  Yang" /></meta><meta name="dc.Creator" content="Jianjun  Chen" /></meta><meta name="dc.Description" content="A series of programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors based on the resorcinol diphenyl ether scaffold were discovered by incorporating hydrophilic moieties in..." /></meta><meta name="Description" content="A series of programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors based on the resorcinol diphenyl ether scaffold were discovered by incorporating hydrophilic moieties in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 2, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01684" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01684" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01684" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01684" /></link>
        
    
    

<title>Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01684" /></meta><meta property="og:title" content="Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0015.jpeg" /></meta><meta property="og:description" content="A series of programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors based on the resorcinol diphenyl ether scaffold were discovered by incorporating hydrophilic moieties into the side chain and converting into the corresponding hydrochloride salt. Among these compounds, P18 showed the highest inhibitory activity against PD-1/PD-L1 with an IC50 value of 9.1 nM in a homogeneous time-resolved fluorescence binding assay. Besides, P18 promoted HepG2 cell death dose dependently in a HepG2/PD-L1 and Jurkat/PD-1 coculture cell model. Further, P18 demonstrated significantly higher water solubility (17.61 mg/mL) and improved pharmacokinetics (e.g., t1/2 of ∼20 h and oral bioavailability of 12%) than the previous analogues. Moreover, P18 was highly effective in suppressing tumor growth in an immune checkpoint humanized mouse model without apparent toxicity. Collectively, these results suggest that compound P18 represents a promising PD-1/PD-L1 inhibitor worthy of further investigation as a potential anticancer agent." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01684"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01684">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01684&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01684&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01684&amp;href=/doi/10.1021/acs.jmedchem.0c01684" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 24</span><span class="cit-fg-pageRange">, 15946-15959</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/24" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01647" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01710" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Binbin Cheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Binbin Cheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Binbin++Cheng">Binbin Cheng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wei Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wei Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wei++Wang">Wei Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xiaoge Niu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xiaoge Niu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xiaoge++Niu">Xiaoge Niu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yichang Ren</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yichang Ren</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yichang++Ren">Yichang Ren</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ting Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ting Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ting++Liu">Ting Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hao Cao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hao Cao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hao++Cao">Hao Cao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuanghu Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuanghu Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuanghu++Wang">Shuanghu Wang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0057-267X" title="Orcid link">http://orcid.org/0000-0002-0057-267X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yingfeng Tu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yingfeng Tu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yingfeng++Tu">Yingfeng Tu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2605-0172" title="Orcid link">http://orcid.org/0000-0003-2605-0172</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jingxuan Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jingxuan Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jingxuan++Chen">Jingxuan Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuwen Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuwen Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuwen++Liu">Shuwen Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6346-5006" title="Orcid link">http://orcid.org/0000-0001-6346-5006</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xuchao Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xuchao Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xuchao++Yang">Xuchao Yang</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Jianjun Chen</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jianjun Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#402a2328252e727100332d356e2524356e232e"><span class="__cf_email__" data-cfemail="84eee7ece1eab6b5c4f7e9f1aae1e0f1aae7ea">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jianjun++Chen">Jianjun Chen</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5668-6572" title="Orcid link">http://orcid.org/0000-0001-5668-6572</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01684&amp;href=/doi/10.1021%2Facs.jmedchem.0c01684" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 24</span><span class="cit-pageRange">, 15946–15959</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 2, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 September 2020</li><li><span class="item_label"><b>Published</b> online</span>2 December 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01684" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01684</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D15946%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBinbin%2BCheng%252C%2BWei%2BWang%252C%2BXiaoge%2BNiu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D24%26contentID%3Dacs.jmedchem.0c01684%26title%3DDiscovery%2Bof%2BNovel%2Band%2BHighly%2BPotent%2BResorcinol%2BDibenzyl%2BEther-Based%2BPD-1%252FPD-L1%2BInhibitors%2Bwith%2BImproved%2BDrug-like%2Band%2BPharmacokinetic%2BProperties%2Bfor%2BCancer%2BTreatment%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D15959%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01684"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2019</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">2</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01684" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Novel and Highly Potent Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Binbin&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Wei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Xiaoge&quot;,&quot;last_name&quot;:&quot;Niu&quot;},{&quot;first_name&quot;:&quot;Yichang&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Ting&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Hao&quot;,&quot;last_name&quot;:&quot;Cao&quot;},{&quot;first_name&quot;:&quot;Shuanghu&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Yingfeng&quot;,&quot;last_name&quot;:&quot;Tu&quot;},{&quot;first_name&quot;:&quot;Jingxuan&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Shuwen&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Xuchao&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Jianjun&quot;,&quot;last_name&quot;:&quot;Chen&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;24&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;15946-15959&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01684&quot;},&quot;abstract&quot;:&quot;A series of programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors based on the resorcinol diphenyl ether scaffold were discovered by incorporating hydrophilic moieties into the side chain and converting into the corresponding hydrochloride salt. Among these compounds, P18 showed the highest inhibitory activity against PD-1/PD-L1 with an IC50 value of 9.1 nM in a homogeneous time-resolved fluorescence binding assay. Besides, P18 promoted HepG2 cell death dose dependently in a HepG2/PD-L1 and Jurkat/PD-1 coculture cell model. Further, P18 demonstrated significantly higher water solubility (17.61 mg/mL) and improved pharmacokinetics (e.g., t1/2 of ∼20 h and oral bioavailability of 12%) than the previous analogues. Moreover, P18 was highly effective in suppressing tumor growth in an immune checkpoint humanized mouse model without apparent toxicity. Collectively, these results suggest that compound P18 represents a promising PD-1/PD-L1 inhibitor worthy of further investigation as a poten&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01684&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01684" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01684&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01684" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01684&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01684" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01684&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01684&amp;href=/doi/10.1021/acs.jmedchem.0c01684" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01684" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01684" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01684%26sid%3Dliteratum%253Aachs%26pmid%3D33264007%26genre%3Darticle%26aulast%3DCheng%26date%3D2020%26atitle%3DDiscovery%2Bof%2BNovel%2Band%2BHighly%2BPotent%2BResorcinol%2BDibenzyl%2BEther-Based%2BPD-1%252FPD-L1%2BInhibitors%2Bwith%2BImproved%2BDrug-like%2Band%2BPharmacokinetic%2BProperties%2Bfor%2BCancer%2BTreatment%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D24%26spage%3D15946%26epage%3D15959%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/24" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/jmcmar.2020.63.issue-24/20201224/jmcmar.2020.63.issue-24.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A series of programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors based on the resorcinol diphenyl ether scaffold were discovered by incorporating hydrophilic moieties into the side chain and converting into the corresponding hydrochloride salt. Among these compounds, <b>P18</b> showed the highest inhibitory activity against PD-1/PD-L1 with an IC<sub>50</sub> value of 9.1 nM in a homogeneous time-resolved fluorescence binding assay. Besides, <b>P18</b> promoted HepG2 cell death dose dependently in a HepG2/PD-L1 and Jurkat/PD-1 coculture cell model. Further, <b>P18</b> demonstrated significantly higher water solubility (17.61 mg/mL) and improved pharmacokinetics (<i>e.g.</i>, <i>t</i><sub>1/2</sub> of ∼20 h and oral bioavailability of 12%) than the previous analogues. Moreover, <b>P18</b> was highly effective in suppressing tumor growth in an immune checkpoint humanized mouse model without apparent toxicity. Collectively, these results suggest that compound <b>P18</b> represents a promising PD-1/PD-L1 inhibitor worthy of further investigation as a potential anticancer agent.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23747" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23747" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Immunotherapy has recently emerged as one of the most rapidly evolving fields in cancer treatment and benefits patients with remarkable clinical efficacy and good clinical responses.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> To date, 10 programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1)-targeting monoclonal antibodies (mAbs) have gained FDA approval for tumor immunotherapy, and hundreds of mAbs are currently under active clinical trials.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> However, mAbs suffer from several disadvantages such as immune-related adverse events, poor pharmacokinetics (PKs) (<i>e.g.</i>, not orally bioavailable), structural instability, and high percentages of unresponsive patients.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> However, small molecules may have the potential to overcome the above problems. Therefore, the search for small molecule inhibitors of PD-1/PD-L1 has been intensified in recent years.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a></div><div class="NLM_p">Over the last decade, a number of potent non-mAbs PD-1/PD-L1 inhibitors and downregulators have been reported, including small molecules, peptidomimetics, and macrocyclic peptides,<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> for example, the BMS-analogues (BMS-202, BMS-8, BMS-1001, BMS-1166, etc.) discovered by the BMS company,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> (+)-JQ-1 as a downregulator of PD-L1 by Fruci <i>et al.</i>,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> and CA-170 by Curis Inc. (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The most advanced PD-1/PD-L1 inhibitor is CA-170, which is currently in phase II clinical trial (NCT02812875). However, recent studies have shown that CA-170 could not directly block PD-1/PD-L1 interaction; therefore, the precise mechanism of action for CA-170 remains unclear.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative small molecule modulators of PD-1/PD-L1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Because of the hydrophobic nature of the binding interface formed in the interface of PD-1 and PD-L1, the current small molecule modulators of PD-1/PD-L1 are highly lipophilic, resulting in low water solubility and poor PK properties (<i>e.g.</i>, low oral bioavailability, <i>F</i> ≤ 5%).<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10,11)</a> Therefore, the identification of water-soluble PD-1/PD-L1 inhibitors with improved oral bioavailability would be of great importance. In continuation of our research interest in PD-1/PD-L1 inhibitors,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> we designed a series of PD-L1 inhibitors based on the resorcinol diphenyl ether scaffold by incorporating hydrophilic moieties into the side chain and converting into the corresponding hydrochloride salt, evaluated for their <i>in vitro</i> inhibitory activity against PD-1/PD-L1, examined the <i>in vivo</i> tumor suppressing effects in an immune humanized mouse model, tested the <i>in vivo</i> cardiotoxicity, and assessed their drug-like properties (<i>e.g.</i>, PKs, oral bioavailability, and aqueous solubility) as detailed below.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47854" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47854" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">Compounds <b>P1–18</b> were synthesized according to the synthetic route as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. First, 5-chloro-2,4-dihydroxybenzaldehyde <b>1</b> was condensed with 1-bromo-3-(bromomethyl)-2-methylbenzene (<b>m1</b>) in dimethylformamide (DMF) to produce intermediate <b>2</b>, followed by a nucleophilic substitution reaction with 3-cyanobenzyl bromide to afford the key intermediate <b>3</b>. Then, intermediate <b>3</b> was coupled with appropriate boronic acids to generate compounds <b>4</b>. Finally, compounds <b>4</b> were subject to a reductive amination or condensation reaction to yield the desired compounds <b>P1–18</b>.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>P1–18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) NaHCO<sub>3</sub>, anhydrous DMF, 60 °C, 2 h, and 40%; (b) Na<sub>2</sub>CO<sub>3</sub>, anhydrous DMF, 80 °C, 0.5 h, and 60%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, DMSO/H<sub>2</sub>O = 10/1, 100 °C, 12 h, and 25–30%; (d) NaBH<sub>3</sub>CN, anhydrous DMF, glacial acetic acid, 80 °C, 2 h, and 15–25%; (e) (i) HATU, DIPEA, DMF, rt, 1 h, and 70–80%; and (ii) 4 M HCl in 1,4-dioxane, DCM, 0 °C, 2 h, and 80–90%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> <i>In Vitro</i> Anti-PD-1/PD-L1 Activity</h3><div class="NLM_p">The inhibitory activity of <b>P1–18</b> against PD-1/PD-L1 was determined by a homogeneous time-resolved fluorescence (HTRF) assay.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> As listed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, the majority of the newly synthesized compounds showed nanomolar activities. Among them, <b>P8</b>, <b>P11</b>, and <b>P18</b>, bearing <i>N</i>-hydroxypiperidine-2-carboxamide and <i>N</i>-(2-aminoethyl)piperidine-2-carboxamide, exhibited the highest PD-1/PD-L1 inhibitory activity with IC<sub>50</sub> values of 39.9, 17.3, and 9.1 nM, respectively. Notably, the activity of compound <b>P18</b> (IC<sub>50</sub> = 9.1 nM), with a hydrophilic side chain, was dramatically higher than that of the positive control BMS-202 (IC<sub>50</sub> = 61.6 nM). However, <b>P1–4</b>, <b>P9–10</b>, <b>P12–13</b>, and <b>P16–17</b>, with a Boc-protected side chain, <i>N</i>-(3-aminopropyl)piperidine-2-carboxamide, <i>N</i>-(4-aminobutyl)piperidine-2-carboxamide, <i>N</i>-(2-hydroxyethyl)piperidine-2-carboxamide, displayed lower inhibitory potency with IC<sub>50</sub>s > 100 nM. In general, replacing the biphenyl moiety with the 2,3-dihydrobenzo[<i>b</i>][1,4]dioxine moiety was well tolerated (<b>P5–P13</b>), suggesting that the binding interface of PD-L1 can accommodate relatively bulky and lipophilic groups in the biphenyl interacting region. On the basis of the structure–activity relationships (SARs) revealed above, it was found that the incorporation of short hydrophilic side chains (<i>e.g.</i> ethylenediamine for <b>P11</b>, <b>P18</b>, and hydroxamate for <b>P8</b>) without steric hindrance seems to be optimal for the inhibitory activity. Therefore, <b>P18</b>, the compound that exhibited the highest PD-1/PD-L1 inhibitory activity (IC<sub>50</sub> = 9.1 nM), was selected for subsequent biological evaluations.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Inhibitory Activities of <b>P1–18</b> against PD-1/PD-L1 <i>In Vitro</i></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0014.gif" alt="" id="gr13" /></img><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Molecular Modeling Studies of Compound P18 with the Dimeric PD-L1</h3><div class="NLM_p">To further elucidate the potential binding mode of these PD-1/PD-L1 inhibitors, molecular modeling studies of <b>P18</b> with the homodimeric PD-L1 was conducted. As anticipated, compound <b>P18</b> fitted nicely in the hydrophobic binding interface of PD-L1, the distal biphenyl, central phenyl ring and benzyl cyanide moieties of <b>P18</b> formed π–π interactions with TYR56 and TYR123 of PD-L1, which may provide strong stabilization upon inhibitor binding (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). Additionally, the hydrophilic tail group of <b>P18</b> interacted with GLN66 and ASP122 of PD-L1 <i>via</i> hydrogen bonds, which might further stabilize the inhibitor/PD-L1 complex. These hydrogen bonds, together with the π–π interactions provided by the biphenyl rings, could contribute to the high binding affinity of <b>P18</b> to the dimeric PD-L1, resulting in its high inhibitory activity.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Docking analysis of compound <b>P18</b> in the hydrophobic binding interface of PD-L1 and (B) orientation of compound <b>P18</b> in the binding interface of the PD-L1 dimer (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIU">5NIU</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> <i>In Vitro</i> Cytotoxicity</h3><div class="NLM_p">In order to study the antitumor immunity effect of the resorcinol dibenzyl ether analogues, we chose six compounds with the most potent PD-1/PD-L1 inhibitory activities and evaluated for their cytotoxic/antiproliferative activities against five cancer cell lines including MCF-7 (human breast cancer cell line), H1299 (human non-small-cell lung cancer cell line), Jurkat T cells, HeLa (human cervical cancer cell line), and HepG2 (human liver hepatocellular cell line). Most of the compounds exhibited little cytotoxicity to cancer cells (<i>e.g.</i>, IC<sub>50</sub> > 5 μM), suggesting that these analogues are unlikely to inhibit the growth of cancer cells directly <i>in vitro</i> at low nanomolar concentrations (<i>e.g.</i>, the IC<sub>50</sub> range for anti-PD-1/PD-L1 activity) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antiproliferative Activities of the Newly Synthesized PD-1/PD-L1 Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±"> </th><th class="rowsep1 colsep0" colspan="5" align="center">cytotoxicity: IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">ID</th><th class="colsep0 rowsep0" align="center" char="±">PD-1/PD-L1 IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">MCF-7</th><th class="colsep0 rowsep0" align="center">H1299</th><th class="colsep0 rowsep0" align="center">HeLa</th><th class="colsep0 rowsep0" align="center">HepG2</th><th class="colsep0 rowsep0" align="center" char="±">Jurkat</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>P7</b></td><td class="colsep0 rowsep0" align="char" char="±">114.8 ± 6.4</td><td class="colsep0 rowsep0" align="left">3.2 ± 0.1</td><td class="colsep0 rowsep0" align="left">3.6 ± 0.7</td><td class="colsep0 rowsep0" align="left">2.8 ± 0.2</td><td class="colsep0 rowsep0" align="left">1.1 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">8.1 ± 0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>P8</b></td><td class="colsep0 rowsep0" align="char" char="±">39.9 ± 2.4</td><td class="colsep0 rowsep0" align="left">7.7 ± 0.4</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">8.3 ± 0.5</td><td class="colsep0 rowsep0" align="left">8.4 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">6.7 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>P11</b></td><td class="colsep0 rowsep0" align="char" char="±">17.3 ± 1.8</td><td class="colsep0 rowsep0" align="left">8.2 ± 1.1</td><td class="colsep0 rowsep0" align="left">8.4 ± 1.2</td><td class="colsep0 rowsep0" align="left">6.2 ± 1.1</td><td class="colsep0 rowsep0" align="left">4.8 ± 0.7</td><td class="colsep0 rowsep0" align="char" char="±">2.3 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>P14</b></td><td class="colsep0 rowsep0" align="char" char="±">89.6 ± 4.4</td><td class="colsep0 rowsep0" align="left">5.9 ± 0.1</td><td class="colsep0 rowsep0" align="left">5.9 ± 0.6</td><td class="colsep0 rowsep0" align="left">4.8 ± 0.3</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">5.7 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>P15</b></td><td class="colsep0 rowsep0" align="char" char="±">98.6 ± 5.9</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char="±">9.8 ± 0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>P18</b></td><td class="colsep0 rowsep0" align="char" char="±">9.1 ± 0.9</td><td class="colsep0 rowsep0" align="left">3.2 ± 0.2</td><td class="colsep0 rowsep0" align="left">3.7 ± 0.1</td><td class="colsep0 rowsep0" align="left">4.1 ± 0.9</td><td class="colsep0 rowsep0" align="left">2.3 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">2.8 ± 0.3</td></tr></tbody></table></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> <i>In Vitro</i> Immune Response Based on Cell Mortality Rate</h3><div class="NLM_p">In order to explore immunoregulatory activities of the newly synthesized compounds, we further evaluated the capability of two of the most potent compounds, <b>P11</b> and <b>P18</b>, to reactivate the immune system suppressed by the activated PD-1/PD-L1 signaling pathway utilizing a reported HepG2/Jurkat coculture cell model.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> As illustrated in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <b>P11</b> and <b>P18</b> dose dependently promoted HepG2 cell death. When treated with <b>P18</b> at 1 μM, the mortality rate of HepG2 cells was elevated by 58.2%, which was significantly higher than that of BMS-202 (18.7%).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of compounds <b>P11</b>, <b>P18</b>, and BMS-202 on the mortality rate of HepG2 cells in a HepG2/Jurkat coculture coculture cell model. Data are presented as mean ± SD, **<i>P</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Physicochemical Properties and Aqueous Solubility of Compound P18</h3><div class="NLM_p">Good physicochemical properties (<i>e.g.</i>, aqueous solubility) is the key to the druggability of a candidate compound.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Therefore, the aqueous solubility and other drug-like properties of compound <b>P18</b> were evaluated. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, the aqueous solubility of compound <b>P18</b> was determined as 17.61 mg/mL at pH 7.4, which was significantly better than that of <b>NP19</b> (12 μg/mL at pH 7.4),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> a highly potent PD-L1 inhibitor identified by us before. Other physicochemical properties of compound <b>P18</b> were also calculated, and most of the parameters [<i>e.g.</i>, hydrogen bond acceptor (HBA) and hydrogen bond donor (HBD)] were found to be in compliance with Lipinski’s rule of five. These results indicated that compound <b>P18</b> has reasonable drug-like properties.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Physicochemical Properties and Aqueous Solubility of Compound <b>P18</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">MW<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">HBA<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">HBD<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">tPSA<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">solubility</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>P18</b></td><td class="colsep0 rowsep0" align="char" char=".">696.15</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">100.61</td><td class="colsep0 rowsep0" align="left">17.61 mg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>NP19</b></td><td class="colsep0 rowsep0" align="char" char=".">555.07</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">91.58</td><td class="colsep0 rowsep0" align="left">12 μg/mL</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">MW: molecular weight.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">HBA: hydrogen bond acceptor atoms.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">HBD: hydrogen bond donor atoms.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">tPSA: topological polar surface area.</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>In Vivo</i> PK Study</h3><div class="NLM_p">Encouraged by the high potency and favorable drug-like properties of compound <b>P18</b>, we further evaluated the PK properties of <b>P18</b> in male Sprague-Dawley (SD) rats with <b>P18</b> administered <i>via</i> intravenous (i.v.) and oral (p.o.) routes. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, after a single intravenous dose of compound <b>P18</b> at 1 mg/kg, the clearance rate (CL), half-life (<i>t</i><sub>1/2</sub>), and apparent distribution volume (<i>V</i><sub><i>z</i></sub>) of <b>P18</b> were determined as 1.3 ± 0.4 L/h/kg, 18.1 ± 8.3 h, and 31 ± 9.6 L/kg, respectively. When <b>P18</b> was given orally at a dose of 10 mg/kg, the half-life (<i>t</i><sub>1/2</sub>) and oral bioavailability (<i>F</i>) were 20.9 ± 9.1 h and 12%, respectively. Notably, <b>P18</b> exhibited significantly longer half-life (18.1 h and 20.9 h for i.v. and p.o., respectively) and markedly better bioavailability (12%) than that of <b>NP19</b> (<i>t</i><sub>1/2</sub> = 1.5 and 10.9 h for i.v. and p.o., respectively; <i>F</i> = 5%).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Primary PK Parameters of <b>P18</b> in SD Rats (<i>n</i> = 6, Mean ± SD)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK parameters</th><th class="colsep0 rowsep0" align="center">i.v. administration (1 mg/kg, <i>n</i> = 6)</th><th class="colsep0 rowsep0" align="center">p.o. administration (10 mg/kg, <i>n</i> = 6)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0–<i>t</i>)</sub> (ng/mL·h)</td><td class="colsep0 rowsep0" align="left">718.8 ± 156.5</td><td class="colsep0 rowsep0" align="left">771.2 ± 123.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0–∞)</sub> (ng/mL·h)</td><td class="colsep0 rowsep0" align="left">831.7 ± 239.1</td><td class="colsep0 rowsep0" align="left">961.3 ± 190.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>(0–<i>t</i>)</sub> (h)</td><td class="colsep0 rowsep0" align="left">11.6 ± 1.7</td><td class="colsep0 rowsep0" align="left">17.2 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRT<sub>(0–∞)</sub> (h)</td><td class="colsep0 rowsep0" align="left">19.9 ± 9.4</td><td class="colsep0 rowsep0" align="left">29.7 ± 8.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">18.1 ± 8.3</td><td class="colsep0 rowsep0" align="left">20.9 ± 9.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.083</td><td class="colsep0 rowsep0" align="left">6.3 ± 0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (L/h/kg)</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.4</td><td class="colsep0 rowsep0" align="left">10.8 ± 2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub><i>z</i></sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">31 ± 9.6</td><td class="colsep0 rowsep0" align="left">310.2 ± 113.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">257.2 ± 70</td><td class="colsep0 rowsep0" align="left">52.7 ± 12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">12</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">AUC, area under the curve; CL, plasma clearance; <i>C</i><sub>max</sub>, maximum plasma concentration; MRT, mean residence time; SD, standard deviation; <i>t</i><sub>1/2</sub>, half-life; <i>T</i><sub>max</sub>, time of maximum plasma concentration.</p></div></div></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> <b>P18</b> Exhibited Similar Binding Affinities to Human PD-L1 and Murine PD-L1 <i>In Vitro</i></h3><div class="NLM_p">To verify whether the human specific PD-L1 inhibitor <b>P18</b> can cross-react with mouse PD-L1, we determined its binding affinity to human PD-L1 and murine PD-L1 by using isothermal titration calorimetry (ITC), surface plasmon resonance (SPR), and circular dichroism (CD) spectroscopy analysis. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>, compound <b>P18</b> exhibited similar binding affinity to human PD-L1 (<i>K</i><sub>D</sub> = 88.3 nM) and murine PD-L1 (<i>K</i><sub>D</sub> = 174 nM). Calorimetric data [Δ<i>G</i> (enthalpy), Δ<i>H</i> (entropy), and −<i>T</i>Δ<i>S</i> (free energy)] revealed that the high binding affinity of compound <b>P18</b> to human PD-L1 or murine PD-L1 was mainly due to hydrogen bonding and van der Waals force, which is consistent with our docking analysis.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Binding Affinity of <b>P18</b> to Human or Murine PD-L1 as Measured by ITC</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">human PD-L1</th><th class="colsep0 rowsep0" align="center">murine PD-L1</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>K</i><sub>D</sub></td><td class="colsep0 rowsep0" align="left">88.3 nM</td><td class="colsep0 rowsep0" align="left">174 nM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Δ<i>H</i> (kcal/mol)</td><td class="colsep0 rowsep0" align="left">–80</td><td class="colsep0 rowsep0" align="left">–80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Δ<i>G</i> (kcal/mol)</td><td class="colsep0 rowsep0" align="left">–9.63</td><td class="colsep0 rowsep0" align="left">–9.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">–<i>T</i>Δ<i>S</i> (kcal/mol)</td><td class="colsep0 rowsep0" align="left">70.4</td><td class="colsep0 rowsep0" align="left">70.8</td></tr></tbody></table></div></div><div class="NLM_p">The high binding affinity of compound <b>P18</b> to human or murine PD-L1 was further confirmed by the SPR experiment. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <b>P18</b> dose dependently binds to human PD-L1 and murine PD-L1 with <i>K</i><sub>D</sub> values of 202 nM and 471 nM, respectively, which is consistent with the ITC results.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Real-time interaction between human PD-L1 and compound <b>P18</b> (A) and murine PD-L1 and compound <b>P18</b> (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Moreover, CD spectroscopy indicated that the conformation of secondary structures of human PD-L1 and murine PD-L1 changed in a similar way when compound <b>P18</b> was mixed with human PD-L1 or mouse PD-L1 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), as compared to the control (human or murine PD-L1 only). Collectively, these results (ITC, SPR, and CD) suggest that <b>P18</b> can bind to both human and murine PD-L1 with nearly equal binding affinities.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Circular dichroism spectra of human PD-L1 in complex with compound <b>P18</b> and (B) CD spectra of murine PD-L1 in complex with compound <b>P18</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> <i>In Vivo</i> Efficacy of Compound P18 in a Humanized Knock-in Mouse Model</h3><div class="NLM_p">Based on the high <i>in vitro</i> PD-1/PD-L1 inhibitory activities, reasonable PKs (<i>e.g.</i>, <i>t</i><sub>1/2</sub> of ∼20 h), and our long-standing interest in melanoma,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> compound <b>P18</b> was selected to evaluate the <i>in vivo</i> tumor suppression efficacy in humanized PD-1 C57BL/6J-<i>Pdcd</i><sup><i>em1(hPDCD1)/Smoc</i></sup> mice bearing B16-F10 melanoma tumors. As exhibited in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>, compound <b>P18</b> showed significant antitumor activity in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A–C) and stable body weight (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D) during treatment. At a dose of 100 mg/kg (intragastric gavage), compound <b>P18</b> decreased the tumor weight and tumor volume by 78.1% and 94.1%, respectively (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B,C). With a dose of 50 mg/kg (intragastric gavage), <b>P18</b> was able to decrease the tumor weight and tumor volume by 69.7 and 89.6%, respectively (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B,C), better than that of vehicle control (0.9% saline solution). Statistical analysis also showed that there is no difference in spleen and thymus weights in human PD-1 knock-in mice (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>E,F).</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Therapeutic effects of compound <b>P18</b> on a human PD-1 knock-in tumor mouse model. (A) Image of tumors; (B) tumor weights; (C) tumor volume; (D) body weight changes; (E) spleen weight; and (F) thymus weight. [**<i>P</i> < 0.05 <i>vs</i> vehicle control, <i>n</i> = 5, one-way analysis of variance (ANOVA).]</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Analysis of Chemokines and Tumor-Infiltrating Lymphocytes</h3><div class="NLM_p">To investigate the effects of compound <b>P18</b> in immune regulation, we first assessed the mRNA expression levels of CXCR3, CXCL9, CXCL10, and PD-L1 in the dissected tumor tissues, as clinical research has demonstrated that intratumoral activity of chemokines such as CXCR3, CXCL9, and CXCL10 is required for the effectiveness of anti-PD-1/PD-L1 therapy, and PD-L1 expression level is another key biomarker for predicting the response rate and therapeutic outcomes after anti-PD-L1 treatment.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> As presented in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, the mRNA levels of CXCR3, CXCL9, and CXCL10 were markedly increased in tumors at high doses (100 mg/kg) (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A–C). Furthermore, the mRNA level of PD-L1 was significantly decreased upon P18 treatment, as compared to the vehicle control group (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>D). These results suggest that <b>P18</b> could significantly activate the immune microenvironment.</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Quantitative RT-PCR analysis of the mRNA expression for CXCR3, CXCL9, CXCL10, and PD-L1 in melanoma tumors. (A) Relative expression of CXCR3 mRNA; (B) relative expression of CXCL9 mRNA; (C) relative expression of CXCL10 mRNA; and (D) relative expression of PD-L1 mRNA. (**<i>P</i> < 0.05, <i>n</i> = 5, one-way ANOVA.)</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To further examine immune regulation, we analyzed tumor-infiltrating lymphocytes (TILs) in melanoma tumor tissues by flow cytometry analysis. The percentages of CD3<sup>+</sup>CD4<sup>+</sup> (helper T) and CD3<sup>+</sup>CD8<sup>+</sup> (cytotoxic T) cells were significantly increased in a dose-dependent manner after treatment with compound <b>P18</b> in melanoma tumors but not in spleen, when compared with the control group (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A–F). Moreover, the protein levels of PD-L1 were significantly decreased upon <b>P18</b> treatment, as compared to vehicle control group (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>G–8J). Taken together, these data suggest that the antitumor activity of <b>P18</b> may be related to the activation of the tumor microenvironment.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Percentages of TILs (CD3<sup>+</sup>CD4<sup>+</sup> cells and CD3<sup>+</sup>CD8<sup>+</sup> cells) in spleen and/or tumor tissues of melanoma-bearing human PD-1 knock-in mice (vehicle control group vs <b>P18</b>-treated groups). (A) Representative examples for TILs in melanoma tumors; (B) representative examples for TILs in spleen; (C) CD3<sup>+</sup>CD4<sup>+</sup> cells in melanoma tumors (<i>n</i> = 5); (D) CD3<sup>+</sup>CD8<sup>+</sup> cells in melanoma tumors (<i>n</i> = 5); (E) spleen CD3<sup>+</sup>CD4<sup>+</sup> cells (<i>n</i> = 5); (F) spleen CD3<sup>+</sup>CD8<sup>+</sup> cells (<i>n</i> = 5); (G) PD-L1 expression levels in melanoma tumors (<i>n</i> = 5); (H) ISO control; (I) PD-L1 expression levels in vehicle control; and (J) PD-L1 expression levels in <b>P18</b> treatment group (**<i>P</i> < 0.05, <i>n</i> = 5, one-way ANOVA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> <i>In Vivo</i> Safety Analyses</h3><div class="NLM_p">To evaluate the <i>in vivo</i> safety profiles of <b>P18</b>, pathohistological analysis was carried out utilizing hematoxylin–eosin (H&E) staining of kidney and liver collected at the end of the <i>in vivo</i> efficacy study. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, no apparent morphological aberration in organ tissues among different treatment groups was observed.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Pathological analysis of liver and kidney tissues collected from human PD-1 knock-in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additionally, serum biochemistry profiling revealed that compound <b>P18</b> had no obvious nephrotoxicity and hepatotoxicity in the human PD-1 knock-in mice compared to the vehicle control (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), as determined by the levels of kidney function [blood urea nitrogen (UREA); creatinine (CRE)] and levels of liver function [alanine aminotransferase (ALT); globulin (GLO); aspartate aminotransferase (AST); albumin/globulin (A/G); albumin (ALB); total protein (TP), etc.].</div><figure id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Serum biochemistry analysis (levels of kidney and liver function in human PD-1 knock-in mice): (A) TP; (B) A/G; (C) ALB; (D) ALT; (E) CRE; (F) GGT; (G) GLO; (H) GLU; (I) UREA; (J) AST; and (K) TBIL. Mean ± SD. <i>P</i> values were analyzed by one-way ANOVA with the vehicle control as the comparison.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Furthermore, the <i>in vivo</i> cardiotoxicity of <b>P18</b> was determined in BALB/c mice at doses of 50 and 100 mg/kg (intragastric administration). During the 14 days of treatment, adverse side effects were not observed in mice. Importantly, <b>P18</b> did not cause cardiotoxicity in normal BALB/c mice based on the electrocardiograms (ECG), as compared to control group (0.9% saline solution) (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A–C). Moreover, blood cell analysis revealed that <b>P18</b> had no myelosuppression as the lymphocyte, granulocyte, and other routine hematological indicators were not markedly changed compared to the control group (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>D). The above results indicate that compound <b>P18</b> has an acceptable safety profile <i>in vivo</i> and is suitable for further development.</div><figure id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Evaluation of <i>in vivo</i> cardiotoxicity and myelosuppression of <b>P18</b> by EGC and blood cell analysis in BALB/c mice. (A) Control group (0.9% saline solution); (B) <b>P18</b> at 100 mg/kg; (C) <b>P18</b> at 50 mg/kg; and (D) blood cell analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47811" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47811" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compared to mAbs targeting the PD-1/PD-L1 pathway, the development of immunotherapeutic small molecules has lagged far behind. However, small molecule modulators of PD-1/PD-L1 have certain advantages over mAbs, for example, better PKs (<i>e.g.</i>, reasonable half-life and oral bioavailability). In terms of pharmacodynamics, small molecule modulators of PD-1/PD-L1 not only target immunosuppressive mechanisms similar to mAbs but may also influence intracellular pathways to degrade or downregulate the mRNA or protein levels of PD-L1 that mAbs are unable to access. However, it remains a challenge for designing small molecule PD-1/PD-L1 modulators because of the highly hydrophobic and relatively flat binding interface formed by PD-1 and PD-L1. The hydrophobic binding interface could also result in the identification of false-positive hits during screening processes. Furthermore, current small molecule inhibitors of PD-L1 are highly lipophilic, which may pose challenges (<i>e.g.</i>, poor PKs and off-target binding) to downstream development of these molecules. Thus, the discovery of orally bioavailable small molecule inhibitors of PD-L1 would be of paramount importance in the field of anti-PD-1/PD-L1 drug discovery.</div><div class="NLM_p last">Continuing with our research interest in small molecule inhibitors of PD-L1, we designed a series of resorcinol diphenyl ether-based PD-L1 inhibitors by introducing hydrophilic moieties into the side chains and converting into the corresponding hydrochloride salt and evaluated for their anti-PD-1/PD-L1 activity. Among these analogues, compound <b>P18</b> showed the strongest activity with an IC<sub>50</sub> value of 9.1 nM (HTRF binding assay). Furthermore, <b>P18</b> promoted HepG2 cell death dose dependently in a HepG2/hPD-L1 and Jurkat/hPD-1 coculture cell model. In addition, <b>P18</b> demonstrated significantly improved drug-like and PK properties (<i>e.g.</i>, water solubility of 17.61 mg/mL, <i>t</i><sub>1/2</sub> of ∼20 h, and oral bioavailability of 12%) over the previous analogues. Molecular modeling study indicated that <b>P18</b> binds well to the PD-L1 binding site. Moreover, <b>P18</b> was highly effective in suppressing tumor growth in an immune checkpoint humanized mouse model without apparent toxicity. Finally, <b>P18</b> did not cause <i>in vivo</i> cardiotoxicity and myelosuppression in BALB/c mice. Our results suggest that the novel resorcinol diphenyl ether-based PD-L1 inhibitors deserve further investigation as potential anticancer agents.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54627" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54627" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Methods</h3><div class="NLM_p">Reagents/solvents were acquired from commercial sources. BMS-202 was purchased from InvivoChem (Libertyville, IL, USA). Reactions were monitored by thin layer chromatography (TLC) with silica gel GF/UV 254. Flash column chromatography was carried out using 300–400 mesh silica gel. Nuclear magnetic resonance (NMR) spectra (<sup>1</sup>H and <sup>13</sup>C) were acquired on a Bruker instrument (AV-400 spectrometer) with tetramethylsilane as an internal standard. High-resolution mass spectrometry (HRMS) data were acquired on a Orbitrap Fusion Tribrid mass spectrometer (Thermo Scientific). The purity of compounds was ≥95%, as analyzed by high-performance liquid chromatography (HPLC) (Shimadzu LC-20A model, UV detection at the wavelength of 254 nm) using a C18 column (4.6 × 150 mm, 5 μm).</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Method A</h4><div class="NLM_p last">A solution of aromatic aldehyde compounds (1.0 equiv), piperidine-2-carboxylic acid (3.0 equiv), AcOH (2 drops), and sodium cyanoborohydride (2.0 equiv) in anhydrous DMF (0.2 M) was stirred at 80 °C for 1 h. The mixture was concentrated under reduced pressure. Purification of the residue by Prep-TLC gave the desired compounds.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> General Method B</h4><div class="NLM_p last">To a solution of carboxylic acids (1.0 equiv) in anhydrous DMF (0.2 M), amine (1.1 equiv), HATU (1.0 equiv), and DIPEA (5.0 equiv) were added. The reaction mixture was stirred at rt for 1 h. The solvent was removed under reduced pressure, and the residue was subject to flash chromatography to provide the final compound.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> General Method C</h4><div class="NLM_p last">4 M HCl in 1,4-dioxane (1 mL) was added to the Boc-protected compound in anhydrous dichloromethane (DCM) (5 mL). The reaction mixture was stirred at 0 °C for 2 h. The solvent was evaporated under vacuum and the resulting residue was used directly without any further purification.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Synthesis of Intermediates <b>1–4</b></h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 4-((3-Bromo-2-methylbenzyl)oxy)-5-chloro-2-hydroxybenzaldehyde (<b>2</b>)</h4><div class="NLM_p last">To a solution of 5-chloro-2,4-dihydroxybenzaldehyde (<b>1</b>) (2.0 g, 11.59 mmol) in DMF (15 mL) was added 1-bromo-3-(bromomethyl)-2-methylbenzene (<b>m1</b>) (3.1 g, 11.60 mmol) and NaHCO<sub>3</sub> (2.0 g, 23.19 mmol). The mixture was stirred at 60 °C for 2 h. TLC (petroleum ether/ethyl acetate = 5:1, <i>R</i><sub>f</sub> = 0.3) showed one new spot formed. The reaction mixture was poured into H<sub>2</sub>O (20 mL), and then the mixture was extracted with ethyl acetate (30 mL × 3). The organic phase was washed with brine (20 mL × 2), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated under vacuum to afford a residue. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 30/1–2/1) to afford <b>2</b> (1.7 g, 75.9%) as a yellow oil. <sup>1</sup>H NMR (400 MHz, DMSO): δ 11.16 (s, 1H), 10.04 (s, 1H), 7.71 (s, 1H), 7.64 (d, <i>J</i> = 7.9 Hz, 1H), 7.50 (d, <i>J</i> = 7.6 Hz, 1H), 7.21 (t, <i>J</i> = 7.7 Hz, 1H), 6.83 (s, 1H), 5.32 (s, 2H), 2.41 (s, 3H).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 3-((5-((3-Bromo-2-methylbenzyl)oxy)-4-chloro-2-formylphenoxy)methyl)benzonitrile (<b>3</b>)</h4><div class="NLM_p last">A mixture of <b>2</b> (1.7 g, 4.78 mmol), Na<sub>2</sub>CO<sub>3</sub> (760 mg, 7.17 mmol), and 3-cyanobenzyl bromide (1.12 g, 5.74 mmol) in DMF (20 mL) was stirred at 80 °C for 30 min. TLC (petroleum ether/ethyl acetate = 3:1, <i>R</i><sub>f</sub> = 0.4) showed that the starting material <b>2</b> was consumed completely. The reaction mixture was poured into H<sub>2</sub>O (20 mL), and then the mixture was extracted with ethyl acetate (30 mL × 3). The organic phase was washed with brine (20 mL × 2), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated under vacuum to afford a residue, which triturated with methyl <i>tert</i>-butyl ether (20 mL) to afford <b>3</b> (1.5 g, 66%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO): δ 10.23 (s, 1H), 8.03 (s, 1H), 7.86 (dd, <i>J</i> = 11.6, 8.2 Hz, 2H), 7.72 (s, 1H), 7.64 (t, <i>J</i> = 7.3 Hz, 2H), 7.51 (d, <i>J</i> = 7.7 Hz, 1H), 7.22 (s, 1H), 7.20 (d, <i>J</i> = 7.8 Hz, 1H), 5.44 (s, 2H), 5.41 (s, 2H), 2.42 (s, 3H).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-formylphenoxy)methyl)benzonitrile (<b>4a</b>)</h4><div class="NLM_p last">A mixture of <b>3</b> (300 mg, 637.28 μmol), (2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)boronic acid (102 mg, 828.5 μmol), Cs<sub>2</sub>CO<sub>3</sub> (416 mg, 1.28 mmol), and Pd(PPh<sub>3</sub>)<sub>4</sub> (20 mg, 17.3 μmol) in DMSO (15 mL) and H<sub>2</sub>O (2 mL) was degassed and heated to 100 °C for 12 h under N<sub>2</sub>, TLC (petroleum ether/ethyl acetate = 1:1, <i>R</i><sub>f</sub> = 0.2) showed that the starting material <b>3</b> was consumed completely, and one new spot formed. The reaction mixture was poured into H<sub>2</sub>O (10 mL), and then the mixture was extracted with ethyl acetate (20 mL × 3). The organic phase was washed with brine (10 mL × 2), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated under vacuum to afford a residue, which was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 30/1–1/1) to afford <b>4a</b> (200 mg, 67%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.34 (s, 1H), 7.93 (s, 1H), 7.74 (s, 1H), 7.70 (d, <i>J</i> = 7.8 Hz, 2H), 7.57 (d, <i>J</i> = 7.7 Hz, 1H), 7.41 (s, 1H), 7.28 (s, 1H), 7.27 (d, <i>J</i> = 1.8 Hz, 1H), 6.94 (d, <i>J</i> = 8.2 Hz, 1H), 6.84 (d, <i>J</i> = 1.9 Hz, 1H), 6.81–6.77 (m, 1H), 6.63 (s, 1H), 5.22 (s, 2H), 5.20 (s, 2H), 4.33 (s, 4H), 2.30 (s, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 186.55, 160.47, 159.88, 143.08, 142.73, 142.62, 137.10, 134.83, 134.14, 133.48, 132.12, 131.32, 130.52, 130.21, 129.73, 127.25, 125.63, 122.44, 119.37, 118.14, 117.04, 116.91, 113.13, 98.72, 70.48, 69.80, 64.40, 16.25.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 3-((4-Chloro-2-formyl-5-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)phenoxy)methyl)benzonitrile (<b>4b</b>)</h4><div class="NLM_p last"><b>4b</b> was prepared from <b>3</b> in a similar manner as described for <b>4a</b>, with phenylboronic acid replacing (2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)boronic acid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 10.35 (s, 1H), 7.94 (s, 1H), 7.75 (s, 1H), 7.72 (s, 1H), 7.70 (s, 1H), 7.57 (t, <i>J</i> = 7.8 Hz, 1H), 7.46 (t, <i>J</i> = 7.2 Hz, 3H), 7.40 (d, <i>J</i> = 7.1 Hz, 1H), 7.33 (d, <i>J</i> = 9.7 Hz, 3H), 7.28 (s, 1H), 6.65 (s, 1H), 5.24 (s, 2H), 5.22 (s, 2H), 2.29 (s, 3H).</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Synthesis of Compounds <b>P1–18</b></h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>tert</i>-Butyl (3-(1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)piperidine-2-carboxamido)propyl)carbamate (<b>P1</b>)</h4><div class="NLM_p last">Yellow oil (11 mg, yield 71%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 7.95 (d, <i>J</i> = 7.8 Hz, 2H), 7.86–7.79 (m, 2H), 7.74 (s, 1H), 7.63 (t, <i>J</i> = 7.7 Hz, 1H), 7.48–7.44 (m, 3H), 7.40 (d, <i>J</i> = 7.3 Hz, 1H), 7.32 (d, <i>J</i> = 7.2 Hz, 2H), 7.28 (d, <i>J</i> = 7.6 Hz, 1H), 7.22 (d, <i>J</i> = 7.1 Hz, 1H), 7.07 (s, 1H), 6.73 (s, 1H), 5.29 (s, 2H), 5.23 (s, 2H), 3.52 (d, <i>J</i> = 13.8 Hz, 1H), 3.26 (d, <i>J</i> = 13.8 Hz, 2H), 3.07–2.96 (m, 2H), 2.87 (d, <i>J</i> = 6.2 Hz, 2H), 2.78 (s, 1H), 2.72 (s, 1H), 2.69 (s, 2H), 2.24 (s, 3H), 1.91 (t, <i>J</i> = 10.7 Hz, 1H), 1.72 (d, <i>J</i> = 12.2 Hz, 1H), 1.66 (d, <i>J</i> = 12.0 Hz, 1H), 1.52 (d, <i>J</i> = 10.2 Hz, 2H), 1.48–1.42 (m, 2H), 1.35 (s, 9H). MS <i>m</i>/<i>z</i>: 737.5 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 20.995 min, purity 95.361%.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-(3-Aminopropyl)-1-(5-chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)piperidine-2-carboxamide Dihydrochloride (<b>P2</b>)</h4><div class="NLM_p last">Yellow oil (5 mg, yield 80%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 9.65 (s, 1H), 9.23 (s, 1H), 8.12 (s, 2H), 8.07 (s, 1H), 7.89 (d, <i>J</i> = 7.9 Hz, 1H), 7.85 (d, <i>J</i> = 7.7 Hz, 1H), 7.65 (t, <i>J</i> = 7.8 Hz, 1H), 7.49 (dd, <i>J</i> = 16.5, 7.3 Hz, 4H), 7.40 (d, <i>J</i> = 7.2 Hz, 1H), 7.34–7.29 (m, 3H), 7.24 (d, <i>J</i> = 5.8 Hz, 2H), 5.39 (s, 2H), 5.34 (s, 2H), 4.15 (t, <i>J</i> = 18.2 Hz, 2H), 3.96 (s, 1H), 3.23 (d, <i>J</i> = 6.3 Hz, 3H), 2.98 (s, 1H), 2.82 (s, 2H), 2.25 (s, 3H), 2.13 (d, <i>J</i> = 13.1 Hz, 1H), 1.97 (s, 1H), 1.81–1.75 (m, 2H), 1.70 (s, 3H), 1.44 (s, 1H). MS <i>m</i>/<i>z</i>: 637.4 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 18.113 min, purity 95.461%.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-(4-Aminobutyl)-1-(5-chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)piperidine-2-carboxamide Dihydrochloride (<b>P3</b>)</h4><div class="NLM_p last">Yellow oil (7 mg, yield 81%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 9.65 (s, 1H), 9.07 (s, 1H), 8.07 (s, 3H), 7.89 (d, <i>J</i> = 7.7 Hz, 1H), 7.85 (d, <i>J</i> = 7.6 Hz, 1H), 7.65 (t, <i>J</i> = 7.7 Hz, 1H), 7.48 (dd, <i>J</i> = 15.6, 7.9 Hz, 4H), 7.39 (t, <i>J</i> = 7.2 Hz, 1H), 7.35–7.28 (m, 3H), 7.24 (d, <i>J</i> = 6.6 Hz, 2H), 5.39 (s, 2H), 5.34 (s, 2H), 4.16 (d, <i>J</i> = 19.7 Hz, 2H), 3.95 (t, <i>J</i> = 9.2 Hz, 1H), 3.23 (d, <i>J</i> = 13.1 Hz, 2H), 3.11 (s, 1H), 2.96 (s, 1H), 2.77 (d, <i>J</i> = 5.8 Hz, 2H), 2.25 (s, 3H), 2.12 (d, <i>J</i> = 12.5 Hz, 1H), 1.99 (s, 1H), 1.71 (t, <i>J</i> = 16.0 Hz, 4H), 1.56 (dd, <i>J</i> = 25.2, 6.9 Hz, 4H), 1.44 (s, 1H), 1.26 (s, 1H). MS <i>m</i>/<i>z</i>: 651.6 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 19.912 min, purity 98.982%.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>tert</i>-Butyl (4-(1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)piperidine-2-carboxamido)butyl)carbamate (<b>P4</b>)</h4><div class="NLM_p last">Yellow oil (21 mg, yield 80%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 7.94 (s, 1H), 7.86–7.78 (m, 2H), 7.69 (s, 1H), 7.63 (t, <i>J</i> = 7.7 Hz, 1H), 7.50–7.45 (m, 3H), 7.40 (d, <i>J</i> = 7.2 Hz, 1H), 7.32 (d, <i>J</i> = 7.0 Hz, 2H), 7.28 (d, <i>J</i> = 7.6 Hz, 1H), 7.22 (d, <i>J</i> = 7.5 Hz, 1H), 7.07 (s, 1H), 6.72 (s, 1H), 5.29 (s, 2H), 5.23 (s, 2H), 3.52 (d, <i>J</i> = 13.7 Hz, 1H), 3.23 (s, 1H), 3.03–2.93 (m, 2H), 2.84 (d, <i>J</i> = 5.6 Hz, 2H), 2.76 (d, <i>J</i> = 15.5 Hz, 1H), 2.70 (d, <i>J</i> = 5.3 Hz, 1H), 2.33 (s, 1H), 2.24 (s, 3H), 1.99 (s, 1H), 1.92 (d, <i>J</i> = 11.7 Hz, 1H), 1.70 (s, 1H), 1.64 (s, 1H), 1.51 (d, <i>J</i> = 13.9 Hz, 2H), 1.37 (s, 1H), 1.32 (d, <i>J</i> = 14.7 Hz, 9H), 1.29 (s, 2H), 1.26 (s, 1H). MS <i>m</i>/<i>z</i>: 751.5 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 20.956 min, purity 95.339%.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)piperidine-2-carboxylic Acid (<b>P5</b>)</h4><div class="NLM_p last">White solid (900 mg, yield 20%).<sup>1</sup>H NMR (400 MHz, DMSO): δ 7.97 (s, 1H), 7.83 (d, <i>J</i> = 7.7 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.45 (d, <i>J</i> = 5.0 Hz, 2H), 7.25 (t, <i>J</i> = 7.5 Hz, 1H), 7.19 (d, <i>J</i> = 6.9 Hz, 1H), 7.10 (s, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.80–6.73 (m, 2H), 5.30 (s, 2H), 5.24 (s, 2H), 4.29 (s, 4H), 3.81 (d, <i>J</i> = 28.9 Hz, 2H), 2.98 (d, <i>J</i> = 8.4 Hz, 1H), 2.43 (s, 1H), 2.24 (s, 3H), 1.98 (s, 1H), 1.86 (s, 1H), 1.72 (d, <i>J</i> = 9.9 Hz, 1H), 1.52 (s, 3H), 1.40 (s, 1H). MS <i>m</i>/<i>z</i>: 654.3 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 17.925 min, purity 98.490%.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>tert</i>-Butyl 4-(1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)piperidine-2-carbonyl)piperazine-1-carboxylate (<b>P6</b>)</h4><div class="NLM_p last">Yellow oil (8 mg, yield 78%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 7.94 (s, 1H), 7.85–7.78 (m, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.44 (d, <i>J</i> = 7.0 Hz, 1H), 7.30 (s, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 7.5 Hz, 1H), 7.06 (s, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.80–6.72 (m, 2H), 5.27 (s, 2H), 5.21 (s, 2H), 4.29 (s, 4H), 3.62 (s, 2H), 3.54 (d, <i>J</i> = 14.4 Hz, 1H), 3.39 (s, 1H), 3.22 (s, 1H), 3.18 (d, <i>J</i> = 5.2 Hz, 1H), 2.91 (d, <i>J</i> = 11.7 Hz, 1H), 2.68 (s, 1H), 2.24 (s, 3H), 2.11 (s, 2H), 2.00 (dd, <i>J</i> = 9.5, 4.9 Hz, 3H), 1.63 (s, 3H), 1.45 (d, <i>J</i> = 5.8 Hz, 3H), 1.39 (s, 9H). MS <i>m</i>/<i>z</i>: 807.5 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 21.248 min, purity 96.608%.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 3-((4-Chloro-5-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-2-((2-(piperazine-1-carbonyl)piperidin-1-yl)methyl)phenoxy)methyl)benzonitrile Dihydrochloride (<b>P7</b>)</h4><div class="NLM_p last">Yellow oil (2 mg, yield 83%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 9.56 (s, 2H), 9.36 (s, 1H), 8.04 (s, 1H), 7.88 (d, <i>J</i> = 7.4 Hz, 2H), 7.67 (t, <i>J</i> = 7.7 Hz, 1H), 7.48 (d, <i>J</i> = 7.1 Hz, 1H), 7.43 (s, 1H), 7.27 (t, <i>J</i> = 7.6 Hz, 1H), 7.24–7.08 (m, 2H), 6.94 (d, <i>J</i> = 8.1 Hz, 1H), 6.82–6.67 (m, 2H), 5.34 (d, <i>J</i> = 14.7 Hz, 4H), 4.29 (s, 4H), 4.13 (d, <i>J</i> = 2.1 Hz, 1H), 3.84 (dd, <i>J</i> = 18.1, 13.7 Hz, 2H), 3.75–3.65 (m, 2H), 3.57 (s, 4H), 3.18 (d, <i>J</i> = 10.9 Hz, 3H), 2.89 (s, 1H), 2.70 (s, 1H), 2.26 (s, 3H), 2.00 (dd, <i>J</i> = 13.2, 9.0 Hz, 2H), 1.71 (s, 2H), 1.56–1.45 (m, 2H). MS <i>m</i>/<i>z</i>: 707.4 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 19.752 min, purity 95.135%.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)-<i>N</i>-hydroxypiperidine-2-carboxamide (<b>P8</b>)</h4><div class="NLM_p last">Luminous yellow oil (3 mg, yield 76%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 10.52 (s, 1H), 8.78 (s, 1H), 7.95 (d, <i>J</i> = 5.5 Hz, 1H), 7.82 (d, <i>J</i> = 7.2 Hz, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.44 (d, <i>J</i> = 5.8 Hz, 2H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 7.0 Hz, 1H), 7.05 (s, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.79–6.72 (m, 2H), 5.28 (s, 2H), 5.21 (s, 2H), 4.29 (s, 4H), 3.47 (d, <i>J</i> = 14.1 Hz, 1H), 3.23 (s, 1H), 2.76 (d, <i>J</i> = 4.9 Hz, 1H), 2.69 (s, 1H), 2.24 (s, 3H), 2.00 (dd, <i>J</i> = 15.1, 7.4 Hz, 1H), 1.90 (d, <i>J</i> = 11.3 Hz, 1H), 1.67 (s, 2H), 1.48 (s, 1H), 1.41–1.35 (m, 1H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 172.30, 153.30, 152.11, 151.07, 150.41, 143.46, 142.00, 139.12, 136.90, 135.04, 134.62, 134.53, 132.16, 130.32, 129.95, 126.12, 122.75, 119.18, 118.13, 117.50, 112.11, 108.28, 106.99, 100.67, 99.65, 70.10, 66.81, 64.87, 64.65, 56.22, 55.71, 31.76, 29.61, 29.09, 16.47. HRMS <i>m</i>/<i>z</i>: calcd for C<sub>37</sub>H<sub>37</sub>O<sub>6</sub>N<sub>3</sub>Cl 654.2365, found 654.2357 [M + H]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 19.605 min, purity 98.619%.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)-<i>N</i>-(2-hydroxyethyl)piperidine-2-carboxamide (<b>P9</b>)</h4><div class="NLM_p last">Yellow oil (10 mg, yield 73%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 7.94 (s, 1H), 7.82 (d, <i>J</i> = 7.8 Hz, 2H), 7.68 (d, <i>J</i> = 5.8 Hz, 1H), 7.64 (d, <i>J</i> = 7.8 Hz, 1H), 7.43 (d, <i>J</i> = 7.1 Hz, 2H), 7.24 (d, <i>J</i> = 7.5 Hz, 1H), 7.18 (d, <i>J</i> = 6.9 Hz, 1H), 7.05 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.79–6.74 (m, 2H), 5.30 (s, 2H), 5.20 (s, 2H), 4.29 (s, 4H), 3.55 (d, <i>J</i> = 13.4 Hz, 1H), 3.17 (d, <i>J</i> = 5.2 Hz, 2H), 3.11 (d, <i>J</i> = 5.9 Hz, 2H), 2.70 (s, 1H), 2.24 (s, 3H), 2.00 (d, <i>J</i> = 4.4 Hz, 1H), 1.94–1.89 (m, 1H), 1.73 (d, <i>J</i> = 13.6 Hz, 1H), 1.65 (d, <i>J</i> = 11.4 Hz, 1H), 1.51 (d, <i>J</i> = 7.2 Hz, 2H), 1.38 (s, 1H). MS <i>m</i>/<i>z</i>: 682.4 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 19.832 min, purity 97.369%.</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>tert</i>-Butyl (2-(1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)piperidine-2-carboxamido)ethyl)carbamate (<b>P10</b>)</h4><div class="NLM_p last">Yellow oil (12 mg, yield 80%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 7.94 (d, <i>J</i> = 10.3 Hz, 1H), 7.82 (d, <i>J</i> = 7.6 Hz, 1H), 7.77 (s, 1H), 7.63 (t, <i>J</i> = 7.7 Hz, 1H), 7.44 (d, <i>J</i> = 11.0 Hz, 2H), 7.24 (t, <i>J</i> = 7.5 Hz, 1H), 7.18 (d, <i>J</i> = 7.2 Hz, 1H), 7.05 (s, 1H), 6.93 (d, <i>J</i> = 8.1 Hz, 1H), 6.76 (dd, <i>J</i> = 11.6, 3.4 Hz, 2H), 5.29 (s, 2H), 5.20 (s, 2H), 4.29 (s, 4H), 3.52 (d, <i>J</i> = 13.4 Hz, 1H), 3.26 (s, 2H), 3.17 (d, <i>J</i> = 5.2 Hz, 1H), 3.07 (dd, <i>J</i> = 12.7, 5.8 Hz, 2H), 2.99–2.91 (m, 2H), 2.75 (d, <i>J</i> = 8.3 Hz, 1H), 2.72–2.65 (m, 2H), 2.24 (s, 3H), 2.00 (d, <i>J</i> = 6.4 Hz, 1H), 1.88 (t, <i>J</i> = 11.5 Hz, 1H), 1.72 (d, <i>J</i> = 11.4 Hz, 1H), 1.64 (d, <i>J</i> = 7.0 Hz, 1H), 1.55–1.45 (m, 2H), 1.37 (d, <i>J</i> = 2.4 Hz, 1H), 1.32 (s, 9H). MS <i>m</i>/<i>z</i>: 781.4 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 20.785 min, purity 97.936%.</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(2-Aminoethyl)-1-(5-chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)piperidine-2-carboxamide Dihydrochloride (<b>P11</b>)</h4><div class="NLM_p last">Yellow oil (4 mg, yield 85%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 9.59 (s, 1H), 9.25 (s, 1H), 8.15 (s, 2H), 8.04 (s, 1H), 7.93–7.80 (m, 2H), 7.66 (t, <i>J</i> = 7.8 Hz, 1H), 7.49 (s, 1H), 7.46 (d, <i>J</i> = 7.1 Hz, 1H), 7.27 (t, <i>J</i> = 7.6 Hz, 1H), 7.20 (d, <i>J</i> = 6.0 Hz, 2H), 6.94 (d, <i>J</i> = 8.2 Hz, 1H), 6.81–6.69 (m, 2H), 5.34 (d, <i>J</i> = 24.6 Hz, 4H), 4.29 (s, 4H), 4.18 (s, 1H), 3.95 (s, 1H), 3.44 (d, <i>J</i> = 4.5 Hz, 2H), 3.24 (d, <i>J</i> = 16.1 Hz, 2H), 2.95 (d, <i>J</i> = 4.9 Hz, 2H), 2.25 (s, 3H), 2.19 (s, 1H), 1.68 (t, <i>J</i> = 12.3 Hz, 3H), 1.44 (d, <i>J</i> = 5.4 Hz, 1H). HRMS <i>m</i>/<i>z</i>: calcd for C<sub>39</sub>H<sub>42</sub>O<sub>5</sub>N<sub>4</sub>Cl, 681.2838; found, 681.2846 [M + H]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 18.933 min, purity 96.852%.</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (2<i>S</i>,4<i>S</i>)-1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)benzyl)-<i>N</i>,4-dihydroxypyrrolidine-2-carboxamide (<b>P12</b>)</h4><div class="NLM_p last">Yellow oil (5 mg, yield 71%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 7.94 (s, 1H), 7.88–7.75 (m, 2H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.44 (d, <i>J</i> = 7.7 Hz, 1H), 7.38 (s, 1H), 7.25 (t, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 7.7 Hz, 1H), 7.08 (s, 1H), 6.93 (d, <i>J</i> = 8.2 Hz, 1H), 6.77 (dd, <i>J</i> = 9.8, 5.0 Hz, 2H), 5.31 (s, 2H), 5.22 (s, 2H), 5.02 (s, 1H), 4.29 (s, 3H), 3.61 (d, <i>J</i> = 20.1 Hz, 2H), 3.53 (s, 1H), 3.17 (d, <i>J</i> = 5.2 Hz, 1H), 2.34 (d, <i>J</i> = 11.2 Hz, 1H), 2.25 (d, <i>J</i> = 10.4 Hz, 3H), 2.09 (d, <i>J</i> = 10.7 Hz, 1H), 1.97 (s, 2H), 1.46 (d, <i>J</i> = 9.0 Hz, 1H). MS <i>m</i>/<i>z</i>: 656.3 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 19.933 min, purity 97.601%.</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>tert</i>-Butyl 4-(1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)piperidine-2-carbonyl)piperazine-1-carboxylate (<b>P13</b>)</h4><div class="NLM_p last">Yellow oil (15 mg, yield 79%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 7.94 (s, 1H), 7.82 (s, 2H), 7.63 (t, <i>J</i> = 7.9 Hz, 1H), 7.47 (t, <i>J</i> = 7.6 Hz, 3H), 7.40 (d, <i>J</i> = 6.5 Hz, 1H), 7.32 (d, <i>J</i> = 7.5 Hz, 4H), 7.28 (d, <i>J</i> = 7.5 Hz, 1H), 7.22 (d, <i>J</i> = 7.4 Hz, 1H), 7.08 (s, 1H), 5.27 (s, 2H), 5.24 (s, 2H), 3.63 (s, 2H), 3.54 (d, <i>J</i> = 13.7 Hz, 1H), 3.43 (s, 1H), 3.39 (s, 1H), 3.24 (s, 2H), 3.13 (s, 1H), 2.91 (d, <i>J</i> = 10.7 Hz, 2H), 2.68 (d, <i>J</i> = 7.4 Hz, 1H), 2.23 (s, 3H), 2.10 (s, 1H), 2.03–1.97 (m, 2H), 1.63 (s, 3H), 1.45 (s, 2H), 1.39 (s, 9H). MS <i>m</i>/<i>z</i>: 749.4 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 21.417 min, purity 97.714%.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 3-((4-Chloro-5-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)-2-((2-(piperazine-1-carbonyl)piperidin-1-yl)methyl)phenoxy)methyl)benzonitrile Dihydrochloride (<b>P14</b>)</h4><div class="NLM_p last">Yellow oil (6 mg, yield 86%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 9.56 (s, 2H), 9.42 (s, 1H), 8.04 (s, 1H), 7.88 (s, 2H), 7.67 (t, <i>J</i> = 7.7 Hz, 1H), 7.52 (d, <i>J</i> = 7.3 Hz, 1H), 7.49 (d, <i>J</i> = 7.5 Hz, 1H), 7.46 (s, 1H), 7.44 (s, 1H), 7.41 (d, <i>J</i> = 7.0 Hz, 1H), 7.32 (t, <i>J</i> = 7.3 Hz, 3H), 7.25 (d, <i>J</i> = 3.4 Hz, 2H), 5.36 (d, <i>J</i> = 8.4 Hz, 4H), 4.65 (s, 1H), 4.13 (s, 2H), 3.83 (d, <i>J</i> = 24.5 Hz, 2H), 3.73 (d, <i>J</i> = 14.4 Hz, 2H), 3.18 (d, <i>J</i> = 4.5 Hz, 3H), 3.07 (s, 1H), 2.88 (s, 1H), 2.25 (s, 3H), 2.03 (dd, <i>J</i> = 17.1, 9.0 Hz, 2H), 1.72 (s, 2H), 1.59–1.50 (m, 2H). MS <i>m</i>/<i>z</i>: 649.5 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 19.843 min, purity 97.804%.</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)-<i>N</i>-hydroxypiperidine-2-carboxamide (<b>P15</b>)</h4><div class="NLM_p last">Luminous yellow oil (5 mg, yield 80%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 10.52 (s, 1H), 8.78 (s, 1H), 7.95 (s, 1H), 7.82 (d, <i>J</i> = 7.7 Hz, 2H), 7.63 (t, <i>J</i> = 7.7 Hz, 1H), 7.55–7.42 (m, 4H), 7.40 (d, <i>J</i> = 7.3 Hz, 1H), 7.32 (d, <i>J</i> = 7.1 Hz, 2H), 7.28 (d, <i>J</i> = 7.6 Hz, 1H), 7.22 (d, <i>J</i> = 7.6 Hz, 1H), 7.07 (s, 1H), 5.28 (s, 2H), 5.23 (s, 2H), 3.48 (d, <i>J</i> = 13.8 Hz, 1H), 3.24 (s, 1H), 3.18 (d, <i>J</i> = 5.0 Hz, 2H), 2.77 (d, <i>J</i> = 11.4 Hz, 1H), 2.24 (s, 3H), 1.88 (d, <i>J</i> = 5.7 Hz, 1H), 1.66 (t, <i>J</i> = 11.7 Hz, 2H), 1.47 (d, <i>J</i> = 5.5 Hz, 2H), 1.38 (s, 1H). MS <i>m</i>/<i>z</i>: 596.3 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 19.786 min, purity 95.929%.</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)-<i>N</i>-(2-hydroxyethyl)piperidine-2-carboxamide (<b>P16</b>)</h4><div class="NLM_p last">Yellow oil (9 mg, yield 78%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 7.94 (s, 1H), 7.82 (d, <i>J</i> = 7.7 Hz, 2H), 7.69 (t, <i>J</i> = 5.6 Hz, 1H), 7.64 (d, <i>J</i> = 7.7 Hz, 1H), 7.46 (d, <i>J</i> = 7.6 Hz, 3H), 7.40 (d, <i>J</i> = 7.1 Hz, 1H), 7.32 (d, <i>J</i> = 7.2 Hz, 2H), 7.28 (d, <i>J</i> = 7.5 Hz, 1H), 7.22 (d, <i>J</i> = 7.4 Hz, 1H), 7.06 (s, 1H), 5.31 (s, 2H), 5.23 (s, 2H), 4.65 (s, 1H), 3.55 (d, <i>J</i> = 13.5 Hz, 1H), 3.27 (s, 1H), 3.15–3.04 (m, 2H), 2.71 (d, <i>J</i> = 16.9 Hz, 3H), 2.24 (s, 3H), 1.91 (t, <i>J</i> = 10.3 Hz, 1H), 1.74 (d, <i>J</i> = 12.0 Hz, 1H), 1.69–1.63 (m, 1H), 1.57–1.49 (m, 2H), 1.37 (d, <i>J</i> = 12.4 Hz, 1H), 1.30 (s, 1H). MS <i>m</i>/<i>z</i>: 624.3 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 20.000 min, purity 97.211%.</div></div><div id="sec4_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>tert</i>-Butyl (2-(1-(5-Chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)piperidine-2-carboxamido)ethyl)carbamate (<b>P17</b>)</h4><div class="NLM_p last">Yellow oil (20 mg, yield 80%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 7.94 (s, 1H), 7.82 (d, <i>J</i> = 7.9 Hz, 2H), 7.77 (t, <i>J</i> = 5.5 Hz, 1H), 7.63 (t, <i>J</i> = 7.7 Hz, 1H), 7.47 (dd, <i>J</i> = 9.4, 5.1 Hz, 4H), 7.40 (d, <i>J</i> = 7.3 Hz, 1H), 7.32 (d, <i>J</i> = 7.1 Hz, 2H), 7.28 (d, <i>J</i> = 7.5 Hz, 1H), 7.22 (d, <i>J</i> = 7.1 Hz, 1H), 7.06 (s, 1H), 5.30 (s, 2H), 5.23 (s, 2H), 3.52 (d, <i>J</i> = 13.6 Hz, 1H), 3.30–3.20 (m, 2H), 3.07 (d, <i>J</i> = 6.4 Hz, 2H), 3.00–2.92 (m, 2H), 2.69 (s, 2H), 2.23 (s, 3H), 1.89 (t, <i>J</i> = 11.0 Hz, 1H), 1.73 (d, <i>J</i> = 15.2 Hz, 1H), 1.64 (d, <i>J</i> = 12.3 Hz, 1H), 1.56–1.48 (m, 2H), 1.38 (d, <i>J</i> = 5.8 Hz, 1H), 1.32 (s, 9H). MS <i>m</i>/<i>z</i>: 723.3 [M + 1]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 20.904 min, purity 95.844%.</div></div><div id="sec4_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-(2-Aminoethyl)-1-(5-chloro-2-((3-cyanobenzyl)oxy)-4-((2-methyl-[1,1′-biphenyl]-3-yl)methoxy)benzyl)piperidine-2-carboxamide Dihydrochloride (<b>P18</b>)</h4><div class="NLM_p last">Yellow oil (10 mg, yield 85%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 9.59 (s, 1H), 9.19 (s, 1H), 8.09 (s, 2H), 8.04 (s, 1H), 7.88 (t, <i>J</i> = 8.7 Hz, 2H), 7.66 (t, <i>J</i> = 7.8 Hz, 1H), 7.49 (dd, <i>J</i> = 14.0, 7.0 Hz, 4H), 7.41 (d, <i>J</i> = 7.3 Hz, 1H), 7.37–7.27 (m, 3H), 7.27–7.19 (m, 2H), 5.37 (s, 2H), 5.33 (s, 2H), 4.18 (s, 2H), 3.99–3.90 (m, 1H), 3.57 (s, 1H), 3.46–3.42 (m, 1H), 3.25 (d, <i>J</i> = 11.2 Hz, 2H), 3.00–2.92 (m, 2H), 2.69 (s, 1H), 2.25 (s, 3H), 2.19 (d, <i>J</i> = 10.6 Hz, 1H), 2.05–1.97 (m, 1H), 1.70 (dd, <i>J</i> = 34.3, 12.8 Hz, 4H), 1.44 (s, 1H). <sup>13</sup>C NMR (101 MHz, DMSO): δ 177.62, 142.76, 141.67, 141.46, 138.23, 135.32, 134.91, 134.56, 133.07, 132.47, 131.64, 130.38, 129.56, 128.81, 128.76, 128.49, 127.53, 127.19, 126.31, 126.14, 125.44, 125.31, 124.58, 123.38, 122.75, 119.13, 111.91, 108.31, 104.41, 99.93, 73.07, 70.13, 66.82, 56.65, 56.17, 41.39, 41.19, 31.46, 29.26, 23.77, 16.19. HRMS <i>m</i>/<i>z</i>: calcd for C<sub>37</sub>H<sub>40</sub>O<sub>3</sub>N<sub>4</sub>Cl, 623.2783; found, 623.2790 [M + H]<sup>+</sup>. HPLC: <i>t</i><sub>R</sub> 19.985 min, purity 97.951%.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>In Vitro</i> PD-1/PD-L1 Binding Assay</h3><div class="NLM_p last">The ability of the newly synthesized compounds in inhibition of PD-1/PD-L1 interaction was studied using a PD-1/PD-L1 HTRF binding assay. The PD-1/PD-L1 binding assay kits (Cisbio, cat. no. 64ICP01PEG&64ICP01PEH) were purchased from Cisbio. The experiments were performed according to the manufacturer’s guidelines.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Determination of the Mortality Rate of HepG2 Cells</h3><div class="NLM_p last">Briefly, HepG2 cells were stimulated with human IFN-γ (catalog# 300-02, Peprotech) to stably express human PD-L1 (hPD-L1); Jurkat T cells were stimulated with PHA-P (catalog# inh-phap, Invivogen) to stably express human PD-1 (hPD-1). HepG2/hPD-L1 and Jurkat T cells (5 × 10<sup>4</sup> in 50 μL and 5 × 10<sup>4</sup> in 50 μL complete media, respectively) were added to the 96-well plates, followed by the addition of different concentrations of test compounds in 100 μL complete media and coculture at 37 °C, 5% CO<sub>2</sub> incubator for 48 h. The supernatants (200 μL) were removed, washed four times with phosphate buffered saline (PBS) to get rid of Jurkat T cells completely. The cytotoxicity of the test compounds was determined using the CCK-8 assay.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>In Vitro</i> Antiproliferative Assay</h3><div class="NLM_p last">The cytotoxicity of the synthesized compounds was determined using the CCK-8 assay. Briefly, the cell lines were incubated at 37 °C in a humidified 5% CO<sub>2</sub> incubator for 24 h in 96-microwell plates. Then, 100 μL of culture medium with 0.1% DMSO containing the test compounds at different concentrations was added to each well and incubated at 37 °C for another 48 h. The optical density was detected with a microplate reader at 450 nm. The IC<sub>50</sub> values were calculated according to the dose-dependent curves.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Water Solubility Studies</h3><div class="NLM_p last">The aqueous solubility of selected compounds was estimated by HPLC. Chromatographic separation of the analytes was performed using a C18-phenyl column with a guard column. HPLC conditions: flow rate, 1 mL/min with a mobile phase of water/MeOH; 70/30 water/MeOH was initially held for 1 min, followed by a linear gradient from 70/30 to 5/95 water/MeOH over 15 min, which was then held for 10 min.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> PK Study in Male SD Rats</h3><div class="NLM_p">All experimental procedures and protocols were reviewed and approved by the National Institutional Animal Care and Ethical Committee of Southern Medical University and were in accordance with the Guide for the Care and Use of Laboratory Animals. Male SD rats (250–260 g) were purchased from Liaoning Changsheng Biotechnology Co., Ltd. Diet was prohibited for 12 h before the experiment but water was freely available. Blood samples (0.5 mL) were collected from the tail vein into heparinized 1.5 mL polythene tubes at 0.0833, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, and 48 h after oral (10 mg/kg) or intravenous (1 mg/kg) administration of compound <b>P18</b>. The LC–MS/MS system used was composed of a Shimadzu HPLC system (Shimadzu Nexera LC-30A, Japan) coupled to an API 4000Q triple quadruple mass spectrometer (Applied Biosystems Sciex, Ontario, Canada). Data processing was made utilizing SCIEX Analyst software (v.1.6.3). Chromatographic separation was performed on an ACQUITY UPLCBEH C18 chromatography column (2.1 × 50 mm, 1.7 μm). The column temperature was set to room temperature (rt). The flow rate is 0.4 mL/min and the injection volume is 5 μL. For HPLC-MS/MS detection, the mobile phase consists of water containing 0.1% formic acid (mobile phase A) and methanol (mobile phase B). In the LC gradient curve, mobile phase B was 30% (v/v) at the beginning, linearly increased from 1 to 2 min to 90%, held for 1.5 min, and then recovered to 5% from 3.5 to 3.6 min. The chromatographic run time for each sample was 4.5 min. Mass spectrometry detection was carried out in the positive ion mode using an electrospray ionization source. The optimized instrument parameters for monitoring the analytes are as follows: source temperature, 550 °C; ion spray voltage: 4500 V; curtain gas: 10 psi; ion source gas 1: 55 psi; ion source gas 2: 55 psi; and dwell time 200 ms. The optimized MS parameters were conducted using multiple reaction monitoring, as described in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. List of Analysts and the Corresponding MRM Parameters</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">substance</th><th class="colsep0 rowsep0" align="center" char=".">precursor ion (<i>m</i>/<i>z</i>)</th><th class="colsep0 rowsep0" align="center" char=".">product ion (<i>m/z</i>)</th><th class="colsep0 rowsep0" align="center" char=".">CE (V)</th><th class="colsep0 rowsep0" align="center" char=".">DP (V)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">P18</td><td class="colsep0 rowsep0" align="char" char=".">623.5</td><td class="colsep0 rowsep0" align="char" char=".">181.0</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS-8 (IS)</td><td class="colsep0 rowsep0" align="char" char=".">494.5</td><td class="colsep0 rowsep0" align="char" char=".">181.2</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr></tbody></table></div></div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> ITC, SPR, and CD Analysis</h3><div class="NLM_p last">All the proteins were obtained from Sino Biological if not otherwise specified: human PD-L1 (cat no: 10084-HNAH) and murine PD-L1 (cat no: 50010-M08H). SPRi measurements were performed with PlexAray HT (Plexera Bioscience, Seattle, WA, USA). Briefly, human/murine PD-L1 was diluted to a final concentration of 0.25 mg/mL with sterile water and printed onto the bare gold-coated PlexArray Nanocapture Sensor Chip, and then <b>P18</b> at different concentrations was injected by a nonpulsatile piston pump into the 30 μL flow cell, which was mounted on the coupling prim. The ITC experiment was performed using a MicroCal PEAQ-ITC (Malvern Panalytical Ltd., UK) according to the manufacturer’s guidelines. CD spectra were recorded on a Chirascan plus ACD (Applied Photophysics Ltd, England). Briefly, human/murine PD-L1 were incubated with sterile water or <b>P18</b> at 25 °C for 30 min, and the CD wave scans were measured from 180 to 260 nm at 4 °C with a bandwidth of 2 nm and a step size of 1 nm.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Immune Checkpoint Humanized Mouse Model</h3><div class="NLM_p last">On the C57BL/6 background, the full-length coding sequence of human PDCD-1 gene was placed immediately downstream of the start codon of the mouse endogenous <i>Pdcd1</i>, followed by a poly(A) element. This guarantees an exclusive expression of human PD-1 in the humanized PD-1 mice (Shanghai Model Organisms Center, Inc., certificate number: 20170010005983). The animal protocols were approved by the National Institutional Animal Care and ethical Committee of Southern Medical University. B16F10 cells growing in a logarithmic growth phase were suspended in PBS at a density of 1 × 10<sup>6</sup> per mL. Each mouse was inoculated subcutaneously with 200 μL containing 2 × 10<sup>5</sup> cells. After tumors reached approximately 50 mm<sup>3</sup> in volume, mice were randomly divided into three groups (<i>n</i> = 5) and treated with compound <b>P18</b> (50, 100 mg/kg) and vehicle (0.9% saline solution), respectively. Compound <b>P18</b> was formulated in 0.9% saline. The drugs were administered <i>via</i> intragastric gavage once a day for 14 days. Animal activity and body weight were monitored during the entire experiment period to assess acute toxicity. Two weeks later, the mice were sacrificed and the tumor tissue and major organ (liver, spleen, thymus, and kidney) samples were collected. The harvested tumor tissue and organs (liver and kidney) were fixed in 4% paraformaldehyde, processed into paraffin routinely, stained with hematoxylin and eosin (H&E), and captured by microscope. Tumor growth inhibition (TGI) value was calculated using the formula: TGI (%) = [1 – <i>W</i><sub>t</sub>/<i>W</i><sub>v</sub>] × 100%, where <i>W</i><sub>t</sub> and <i>W</i><sub>v</sub> are the mean tumor weights of treatment group and vehicle control.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Flow Cytometry</h3><div class="NLM_p last">Organs of mice were harvested and cells were isolated by mechanical dissociation using 40 μm cell strainers. Red blood cells were lysed by ACK lysis buffer (Beyotime). The cells were stained for 30 min at 4 °C for flow cytometry using antibodies against the following targets and isotype controls, both obtained from BioLegend if not otherwise specified: FITC anti-mouse CD3 antibody (cat no: 100204, LOT: B249620), APC anti-mouse CD8a antibody (cat no: 100711, LOT: B280032), PE anti-mouse CD4 antibody (cat no: 100407, LOT: B266389), anti-mouse-PD-L1-PE antibody (cat#: 124307, Lot: B284420), and Rat IgG2b K isotype control PE (cat#: 400608, Lot: B156144). Flow cytometry for murine cells was performed on a BD AccuriC6, and data was analyzed using FlowJo (Tree Star v7.6.1).</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> qPCR Analysis of the mRNA Expression for CXCR3, CXCL9, CXCL10, and PD-L1 in Melanoma Tumors</h3><div class="NLM_p last">The primer sequences for the detection of CXCL9 were 5′-TCTGGCTTCCAGAGCCACAC-3′ and 5′-TCTAGCTCACCAGCAAACAGACA-3′, for CXCR3 were 5′-GCCAAGCCATGTACCTTGAG-3′ and 5′-TCAGGCTGAAATCCTGTGG-3′, for CD274 were 5′-TGGCAGGAGAGGAGGACCTT-3′ and 5′-TGTAGTCCGCACCACCGTAG-3′, and for CXCL10 were 5′-GAGGGCCATAGGGAAGCTTGA-3′ and 5′-GTGTGTGCGTGGCTTCACTC-3′. All samples were normalized using GAPDH detected using 5′-GGAAAGCTGTGGCGTGATGG-3′ and 5′-AGCTCTGGGATGACCTTGCC-3′ primers.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> <i>In Vivo</i> Cardiotoxicity by ECG and Blood Cell Analysis</h3><div class="NLM_p last">BALB/c mice from Liaoning Changsheng Biotechnology Co., Ltd., aged 6–8 weeks old, were used to study the cardiotoxicity of <b>P18</b>. <b>P18</b> was administered <i>via</i> intragastric gavage once a day for 14 days. The vehicle group was administered with 0.9% saline solution. Instrument used: PowerLab (ADI Instruments Castle Hill, NSW, Australia). Electrodes were inserted into the right forelimb (cathode), left limb (anode), and right hind limb (ground) subcutaneously. The right hind limb serves as the reference electrode. The whole blood was also collected into a heparin sodium anticoagulation tube used for blood cell analysis.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Statistical Analysis</h3><div class="NLM_p last">Data was analyzed using Prism Software 5.0. Data was provided as mean ± SD unless otherwise indicated. The statistical significance (<i>P</i> < 0.05) was calculated by one-way ANOVA.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Molecular Docking</h3><div class="NLM_p last">Molecular graphic manipulations and visualizations were performed using Glide 7.4. The X-ray structures of PD-L1 cocrystals were retrieved from the PDB (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIU">5NIU</a>).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i64"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01684" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01684?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01684</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H NMR, <sup>13</sup>C NMR, HRMS, and HPLC spectra (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01684/suppl_file/jm0c01684_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01684/suppl_file/jm0c01684_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIU">5NIU</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01684/suppl_file/jm0c01684_si_003.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01684/suppl_file/jm0c01684_si_001.pdf">jm0c01684_si_001.pdf (3.37 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01684/suppl_file/jm0c01684_si_002.csv">jm0c01684_si_002.csv (2.48 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01684/suppl_file/jm0c01684_si_003.pdb">jm0c01684_si_003.pdb (399.78 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01684" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jianjun Chen</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical Sciences,
Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5668-6572" title="Orcid link">http://orcid.org/0000-0001-5668-6572</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#4f252c272a217d7e0f3c223a612a2b3a612c21"><span class="__cf_email__" data-cfemail="0a6069626f64383b4a79677f246f6e7f246964">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Binbin Cheng</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical Sciences,
Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wei Wang</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical Sciences,
Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiaoge Niu</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical Sciences,
Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yichang Ren</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical Sciences,
Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ting Liu</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical Sciences,
Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hao Cao</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical Sciences,
Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuanghu Wang</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical Sciences,
Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0057-267X" title="Orcid link">http://orcid.org/0000-0002-0057-267X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yingfeng Tu</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical Sciences,
Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2605-0172" title="Orcid link">http://orcid.org/0000-0003-2605-0172</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jingxuan Chen</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical Sciences,
Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuwen Liu</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical Sciences,
Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6346-5006" title="Orcid link">http://orcid.org/0000-0001-6346-5006</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xuchao Yang</span> - <span class="hlFld-Affiliation affiliation">School of Pharmaceutical Sciences,
Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i65">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37107" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37107" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the International Science and Technology Cooperation Projects of Guangdong Province of China (no. G819310411) and the scientific research project of high-level talents in Southern Medical University (no. C1051008).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the plasma concentration–time curve</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum plasma concentration</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">circular dichroism spectroscopy</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">plasma clearance</p></td></tr><tr><td class="NLM_term">H&E</td><td class="NLM_def"><p class="first last">hematoxylin and eosin</p></td></tr><tr><td class="NLM_term">HTRF</td><td class="NLM_def"><p class="first last">homogeneous time-resolved fluorescence</p></td></tr><tr><td class="NLM_term">ITC</td><td class="NLM_def"><p class="first last">isothermal titration calorimetry</p></td></tr><tr><td class="NLM_term">MRT</td><td class="NLM_def"><p class="first last">mean residence time</p></td></tr><tr><td class="NLM_term">mAbs</td><td class="NLM_def"><p class="first last">monoclonal antibodies</p></td></tr><tr><td class="NLM_term">PD-1</td><td class="NLM_def"><p class="first last">programmed cell death-1</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed cell death ligand 1</p></td></tr><tr><td class="NLM_term">SARs</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum plasma time</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 19 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shekarian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valsesia-Wittmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marabelle, A.</span></span> <span> </span><span class="NLM_article-title">Paradigm shift in oncology: targeting the immune system rather than cancer cells</span>. <i>Mutagenesis</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1093/mutage/geu073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1093%2Fmutage%2Fgeu073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=25688113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaqs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=205-211&author=T.+Shekarianauthor=S.+Valsesia-Wittmannauthor=C.+Cauxauthor=A.+Marabelle&title=Paradigm+shift+in+oncology%3A+targeting+the+immune+system+rather+than+cancer+cells&doi=10.1093%2Fmutage%2Fgeu073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Paradigm shift in oncology: targeting the immune system rather than cancer cells</span></div><div class="casAuthors">Shekarian, Tala; Valsesia-Wittmann, Sandrine; Caux, Christophe; Marabelle, Aurelien</div><div class="citationInfo"><span class="NLM_cas:title">Mutagenesis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-211</span>CODEN:
                <span class="NLM_cas:coden">MUTAEX</span>;
        ISSN:<span class="NLM_cas:issn">0267-8357</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The clin. benefits obtained with rituximab in the treatment of CD20+ B-cell malignancies and of imatinib in the treatment of Phi+ leukemias have opened a new era in oncol., transforming the concepts of tumor-targeted therapies and personalised medicine into reality.  Since then, many tumor-targeted monoclonal antibodies and tyrosine kinase inhibitors have been approved for the treatment of cancers.  Compared to conventional chemotherapies, these new drugs have more specificity against cancer cells and less systemic toxicities.  However, like conventional chemotherapies, they often provide limited therapeutic benefits with short-lasting tumor responses as the vast majority of cancers become resistant to these drugs over time.  Therefore, tumor-targeted therapies are an incremental innovation as compared to historical chemotherapies.  Recently, a paradigm shift has been brought to the clinic with drugs targeting immune cells rather than cancer cells with the aim of stimulating the anti-tumor immune response of patients against their own cancer.  Immunomodulatory drugs such as anti-CTLA4 and anti-PD-1 have generated long-lasting tumor responses when used as single agent in patients with refractory/relapsing cancers such as metastatic melanomas, renal cell carcinoma or non-small-cell lung carcinoma.  These new immune-targeted therapies are therefore a disruptive innovation in cancer treatment: they demonstrate that long-lasting clin. benefits could be obtained by targeting mols. involved in the immune tolerance of cancer cells rather than by targeting oncogenic drivers or antigens expressed by cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIgftDslSuLbVg90H21EOLACvtfcHk0lhizH2xEQv4uQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaqs73L&md5=ca56e09fd20963569e1829a8c91d7759</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Fmutage%2Fgeu073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fmutage%252Fgeu073%26sid%3Dliteratum%253Aachs%26aulast%3DShekarian%26aufirst%3DT.%26aulast%3DValsesia-Wittmann%26aufirst%3DS.%26aulast%3DCaux%26aufirst%3DC.%26aulast%3DMarabelle%26aufirst%3DA.%26atitle%3DParadigm%2520shift%2520in%2520oncology%253A%2520targeting%2520the%2520immune%2520system%2520rather%2520than%2520cancer%2520cells%26jtitle%3DMutagenesis%26date%3D2015%26volume%3D30%26spage%3D205%26epage%3D211%26doi%3D10.1093%2Fmutage%2Fgeu073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanmeerbeek, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprooten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ruysscher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejpar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fucikova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spisek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitvogel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, A. D.</span></span> <span> </span><span class="NLM_article-title">Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1703449</span>, <span class="refDoi"> DOI: 10.1080/2162402X.2019.1703449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1080%2F2162402X.2019.1703449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=32002302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVOgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=1703449&author=I.+Vanmeerbeekauthor=J.+Sprootenauthor=D.+De+Ruysscherauthor=S.+Tejparauthor=P.+Vandenbergheauthor=J.+Fucikovaauthor=R.+Spisekauthor=L.+Zitvogelauthor=G.+Kroemerauthor=L.+Galluzziauthor=A.+D.+Garg&title=Trial+watch%3A+chemotherapy-induced+immunogenic+cell+death+in+immuno-oncology&doi=10.1080%2F2162402X.2019.1703449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology</span></div><div class="casAuthors">Vanmeerbeek, Isaure; Sprooten, Jenny; De Ruysscher, Dirk; Tejpar, Sabine; Vandenberghe, Peter; Fucikova, Jitka; Spisek, Radek; Zitvogel, Laurence; Kroemer, Guido; Galluzzi, Lorenzo; Garg, Abhishek D.</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1703449/1-1703449/24</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  The term 'immunogenic cell death' (ICD) denotes an immunol. unique type of regulated cell death that enables, rather than suppresses, T cell-driven immune responses that are specific for antigens derived from the dying cells.  The ability of ICD to elicit adaptive immunity heavily relies on the immunogenicity of dying cells, implying that such cells must encode and present antigens not covered by central tolerance (antigenicity), and deliver immunostimulatory mols. such as damage-assocd. mol. patterns and cytokines (adjuvanticity).  Moreover, the host immune system must be equipped to detect the antigenicity and adjuvanticity of dying cells.  As cancer (but not normal) cells express several antigens not covered by central tolerance, they can be driven into ICD by some therapeutic agents, including (but not limited to) chemotherapeutics of the anthracycline family, oxaliplatin and bortezomib, as well as radiation therapy.  In this Trial Watch, we describe current trends in the preclin. and clin. development of ICD-eliciting chemotherapy as partner for immunotherapy, with a focus on trials assessing efficacy in the context of immunomonitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGNLShZG_SZLVg90H21EOLACvtfcHk0liJSE9_sz7FnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVOgsQ%253D%253D&md5=207cf4aab92fe3a45b7477fb0bb5e870</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2019.1703449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2019.1703449%26sid%3Dliteratum%253Aachs%26aulast%3DVanmeerbeek%26aufirst%3DI.%26aulast%3DSprooten%26aufirst%3DJ.%26aulast%3DDe%2BRuysscher%26aufirst%3DD.%26aulast%3DTejpar%26aufirst%3DS.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DFucikova%26aufirst%3DJ.%26aulast%3DSpisek%26aufirst%3DR.%26aulast%3DZitvogel%26aufirst%3DL.%26aulast%3DKroemer%26aufirst%3DG.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DGarg%26aufirst%3DA.%2BD.%26atitle%3DTrial%2520watch%253A%2520chemotherapy-induced%2520immunogenic%2520cell%2520death%2520in%2520immuno-oncology%26jtitle%3DOncoimmunology%26date%3D2020%26volume%3D9%26spage%3D1703449%26doi%3D10.1080%2F2162402X.2019.1703449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betof, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearden, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapazzo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brohl, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ancell, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eroglu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoushtari, A. N.</span></span> <span> </span><span class="NLM_article-title">Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1093%2Fannonc%2Fmdx642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=29045547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A280%3ADC%252BC1M7itVCltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=250-255&author=M.+H.+Pollackauthor=A.+Betofauthor=H.+Deardenauthor=K.+Rapazzoauthor=I.+Valentineauthor=A.+S.+Brohlauthor=K.+K.+Ancellauthor=G.+V.+Longauthor=A.+M.+Menziesauthor=Z.+Erogluauthor=D.+B.+Johnsonauthor=A.+N.+Shoushtari&title=Safety+of+resuming+anti-PD-1+in+patients+with+immune-related+adverse+events+%28irAEs%29+during+combined+anti-CTLA-4+and+anti-PD1+in+metastatic+melanoma&doi=10.1093%2Fannonc%2Fmdx642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma</span></div><div class="casAuthors">Pollack M H; Pollack M H; Betof A; Shoushtari A N; Dearden H; Long G V; Menzies A M; Rapazzo K; Ancell K K; Johnson D B; Rapazzo K; Ancell K K; Johnson D B; Valentine I; Brohl A S; Eroglu Z; Long G V; Menzies A M; Long G V; Menzies A M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">250-255</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Combined cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) blockade induces high rates of immune-related adverse events (irAEs).  The safety of resuming anti-PD-1 in patients who discontinue combination therapy due to irAEs is not known.  Patients and methods:  We assessed patients who experienced clinically significant irAEs from combined CTLA-4 and PD-1 blockade leading to treatment discontinuation at four academic centers.  We assessed the safety of resuming anti-PD-1 in terms of recurrent and distinct irAEs.  Results:  Eighty patients discontinued combination therapy due to irAEs, including colitis (41%), hepatitis (36%), and pneumonitis (4%).  Of these, 96% received corticosteroids and 21% received additional immunosuppression (e.g. infliximab).  All were rechallenged with anti-PD-1, and 14 (18%) had recurrent irAEs at a median of 14 days after therapy resumption (six grade 1-2, seven grade 3-4, and one grade 5 Steven-Johnson Syndrome).  Colitis was less likely to recur than other irAEs (6% versus 28%, P = 0.01).  Clinically significant but distinct toxicities occurred in an additional 17 (21%) patients (11 grade 1-2 and 6 grade 3-4).  Duration of steroid taper, severity of initial irAEs and use of additional immunosuppressants did not predict for toxicity on rechallenge, although patients remaining on steroid therapy at anti-PD-1 resumption had higher rates of toxicities (55% versus 31%, P = 0.03).  Conclusions:  Patients who discontinued CTLA-4/PD-1 blockade for severe irAEs had relatively high rates of recurrent or distinct toxicities with anti-PD-1 resumption.  However, many patients, particularly with combination-induced colitis, tolerated anti-PD-1 rechallenge well, and this approach can be considered in selected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqAkqru7T6kdXdcedVHT5tfW6udTcc2eZBJAGaGOUd77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7itVCltA%253D%253D&md5=39b9a61c164e6d6b1eb7fb1210c3cd24</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx642%26sid%3Dliteratum%253Aachs%26aulast%3DPollack%26aufirst%3DM.%2BH.%26aulast%3DBetof%26aufirst%3DA.%26aulast%3DDearden%26aufirst%3DH.%26aulast%3DRapazzo%26aufirst%3DK.%26aulast%3DValentine%26aufirst%3DI.%26aulast%3DBrohl%26aufirst%3DA.%2BS.%26aulast%3DAncell%26aufirst%3DK.%2BK.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DMenzies%26aufirst%3DA.%2BM.%26aulast%3DEroglu%26aufirst%3DZ.%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DShoushtari%26aufirst%3DA.%2BN.%26atitle%3DSafety%2520of%2520resuming%2520anti-PD-1%2520in%2520patients%2520with%2520immune-related%2520adverse%2520events%2520%2528irAEs%2529%2520during%2520combined%2520anti-CTLA-4%2520and%2520anti-PD1%2520in%2520metastatic%2520melanoma%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3D250%26epage%3D255%26doi%3D10.1093%2Fannonc%2Fmdx642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">180</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.2174/1568026619666190308131805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.2174%2F1568026619666190308131805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=30854972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGhtL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=180-185&author=S.+Chenauthor=Z.+Songauthor=A.+Zhang&title=Small-Molecule+Immuno-Oncology+Therapy%3A+Advances%2C+Challenges+and+New+Directions&doi=10.2174%2F1568026619666190308131805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions</span></div><div class="casAuthors">Chen, Shulun; Song, Zilan; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">180-185</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Oncol. immunotherapy has gained significant advances in recent years and benefits cancer patients with superior efficacy and superior clin. responses.  Currently over ten immune checkpoint antibodies targeting CTLA-4 and PD-1/PD-L1 have received regulatory approval worldwide and over thousands are under active clin. trials.  However, compared to the rapid advance of Monoclonal Antibody (mAb), studies on immunotherapeutic small mols. have far lagged behind.  Small mol. immunotherapy not only can target immunosuppressive mechanisms similar to mAbs, but also can stimulate intracellular pathways downstream of checkpoint proteins in innate or adaptive immune cells that mAbs are unable to access.  Therefore, small mol. immunotherapy can provide an alternative treatment modality either alone or complementary to or synergistic with extracellular checkpoint mAbs to address low clin. response and drug resistance.  Fortunately, remarkable progress has achieved recently in the pursuit of small mol. immunotherapy.  This review intends to provide a timely highlight on those clin. investigated small mols. targeting PD-1/PD-L1, IDO1, and STING.  The most advanced IDO1 inhibitor epacadostat have been aggressively progressed into multiple clin. testings.  Small mol. PD-1/PD-L1 inhibitors and STING activators are still in a premature state and their decisive application needs to wait for the ongoing clin. outcomes.  Since no small mol. immunotherapy has been approved yet, the future research should continue to focus on discovery of novel small mols. with distinct chemo-types and higher potency, identification of biomarkers to precisely stratify patients, as well as validation of many other immune-therapeutic targets, such as LAG3, KIRs, TIM-3, VISTA, B7-H3, and TIGIT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIg_rDysKA6LVg90H21EOLACvtfcHk0ljLzZlg09Z0rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGhtL7E&md5=944b0fc0de82574b1a24f3e910eaccf4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190308131805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190308131805%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DSmall-Molecule%2520Immuno-Oncology%2520Therapy%253A%2520Advances%252C%2520Challenges%2520and%2520New%2520Directions%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D180%26epage%3D185%26doi%3D10.2174%2F1568026619666190308131805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, W.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Recent advances in small molecule based cancer immunotherapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">582</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1016%2Fj.ejmech.2018.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=30125720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=582-598&author=B.+Chengauthor=W.-E.+Yuanauthor=J.+Suauthor=Y.+Liuauthor=J.+Chen&title=Recent+advances+in+small+molecule+based+cancer+immunotherapy&doi=10.1016%2Fj.ejmech.2018.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in small molecule based cancer immunotherapy</span></div><div class="casAuthors">Cheng, Binbin; Yuan, Wei-En; Su, Jing; Liu, Yao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">582-598</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Immunotherapy has been increasingly utilized for the treatment of cancer.  Currently available cancer immunotherapies mainly involve the use of antibodies, which have advantages in terms of pharmacodynamics such as efficacy and specificity, however, they exhibit disadvantages in regard to the pharmacokinetics including but not limited to poor tissue and tumor penetration, very long half-life, and the lack of oral bioavailability.  Also they are immunogenic and may cause undesired side effects.  In addn., they are difficult and expensive to produce.  In contrast to therapeutic antibodies, small mol. immuno-oncol. agents generally have favorable pharmacokinetics, for example, better oral bioavailability, higher tissue and tumor penetration, reasonable half-lives etc.  Furthermore, some small mols. are highly selective and efficacious with benign toxicity profiles.  Therefore, small mol. immuno-oncol. agents have the potential to overcome the drawbacks of therapeutic antibodies, and they can complement existing therapeutic antibodies and may also be used in combination with antibodies to achieve synergistic effects.  In this article, we summarize the current advances in the field of small mol. approaches in tumor immunol. which include the small mols. in clin. trials and preclin. studies, and the reported crystal structures of small mols. and their target proteins as well as the binding interactions between small mols. and the targets.  The tumorigenesis mechanism of different targets (the programmed cell death 1/programmed cell death ligand 1(PD1/PD-L1), retinoic acid-related orphan receptor-gamma t (RORγt), Chemokine receptor, Stimulator of Interferon Genes (Sting), Indoleamine 2,3-dioxygenase (IDO), toll-like receptors (TLR) etc.) are also elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvYDM1Fp9HUbVg90H21EOLACvtfcHk0ljLzZlg09Z0rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb%252FP&md5=e15fa8048cf9b12ecd494d9ff8db8be5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DW.-E.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DRecent%2520advances%2520in%2520small%2520molecule%2520based%2520cancer%2520immunotherapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D582%26epage%3D598%26doi%3D10.1016%2Fj.ejmech.2018.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Small-molecule immune checkpoint inhibitors targeting PD-1/PD-L1 and other emerging checkpoint pathways</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1007/s40259-018-0303-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1007%2Fs40259-018-0303-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=30168070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Wkt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=481-497&author=P.+G.+Sasikumarauthor=M.+Ramachandra&title=Small-molecule+immune+checkpoint+inhibitors+targeting+PD-1%2FPD-L1+and+other+emerging+checkpoint+pathways&doi=10.1007%2Fs40259-018-0303-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways</span></div><div class="casAuthors">Sasikumar, Pottayil G.; Ramachandra, Murali</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">481-497</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Advances in harnessing the immune system for cancer treatment have been spectacular in recent years as witnessed by the approval of a no. of antibodies targeting the PD-1/PD-L1 immune checkpoint pathway spanning an expanding list of indications.  However, it is well recognized that while these antibodies show impressive clin. activity, they suffer from shortcomings including the failure to show response in a majority of patients, their need to be administered by i.v. injection, and immune-related adverse events due to the breaking of immune self-tolerance.  Small-mol.-based therapeutic approaches offer the potential to address the shortcomings of these antibody-based checkpoint inhibitors.  In the first part of this review, we discuss the rationale for small-mol.-based checkpoint therapy followed by efforts on the discovery of small-mol.-based approaches targeting the PD-1/PD-L1 axis and other immune checkpoint pathways.  In the latter part of the article, we describe small-mol. inhibitors simultaneously targeting two non-redundant checkpoint inhibitor pathways as an approach to improve the response rate.  A brief review of the progress of an oral small-mol. checkpoint inhibitor currently in clin. development is presented at the end.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojNSkErWJotrVg90H21EOLACvtfcHk0ljLzZlg09Z0rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Wkt7rM&md5=9c411ae13233e05057b9b3e4a014a7ee</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs40259-018-0303-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-018-0303-4%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%26aulast%3DRamachandra%26aufirst%3DM.%26atitle%3DSmall-molecule%2520immune%2520checkpoint%2520inhibitors%2520targeting%2520PD-1%252FPD-L1%2520and%2520other%2520emerging%2520checkpoint%2520pathways%26jtitle%3DBioDrugs%26date%3D2018%26volume%3D32%26spage%3D481%26epage%3D497%26doi%3D10.1007%2Fs40259-018-0303-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Törner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5857</span>– <span class="NLM_lpage">5867</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFeisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5857-5867&author=K.+Guzikauthor=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Magieraauthor=B.+Musielakauthor=R.+T%C3%B6rnerauthor=L.+Skalniakauthor=A.+D%C3%B6mlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Small-molecule+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+death-ligand+1+%28PD-1%2FPD-L1%29+interaction+via+transiently+induced+protein+states+and+dimerization+of+PD-L1&doi=10.1021%2Facs.jmedchem.7b00293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1</span></div><div class="casAuthors">Guzik, Katarzyna; Zak, Krzysztof M.; Grudnik, Przemyslaw; Magiera, Katarzyna; Musielak, Bogdan; Torner, Ricarda; Skalniak, Lukasz; Domling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5857-5867</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockade of the PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provided significant advances in cancer treatment.  The antibody-based immunotherapies carry a no. of disadvantages such as the high cost of the antibodies, their limited half-life, and immunogenicity.  Development of small-mol. PD-1/PD-L1 inhibitors that could overcome these drawbacks is slow because of the incomplete structural information for this pathway.  The first chem. PD-1/PD-L1 inhibitors have been recently disclosed by Bristol-Myers Squibb.  Here we present NMR and X-ray characterization for the two classes of these inhibitors.  The X-ray structures of the PD-L1/inhibitor complexes reveal one inhibitor mol. located at the center of the PD-L1 homodimer, filling a deep hydrophobic channel-like pocket between two PD-L1 mols.  Derivs. of (2-methyl-3-biphenylyl)methanol exhibit the structures capped on one side of the channel, whereas the compds. based on [3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methanol induce an enlarged interaction interface that results in the open "face-back" tunnel through the PD-L1 dimer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppmfSesG1M6rVg90H21EOLACvtfcHk0ljSQG1SoW38yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFeisLc%253D&md5=c039796cda3b9ef92a0ed3b10b11932b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00293%26sid%3Dliteratum%253Aachs%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DT%25C3%25B6rner%26aufirst%3DR.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520%2528PD-1%252FPD-L1%2529%2520interaction%2520via%2520transiently%2520induced%2520protein%2520states%2520and%2520dimerization%2520of%2520PD-L1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5857%26epage%3D5867%26doi%3D10.1021%2Facs.jmedchem.7b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melaiu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chierici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldrini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romania, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alicandro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furlanello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruci, D.</span></span> <span> </span><span class="NLM_article-title">PD-L1 is a therapeutic target of the bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4462</span>– <span class="NLM_lpage">4472</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-16-2601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1158%2F1078-0432.ccr-16-2601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=28270499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Ghu7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4462-4472&author=O.+Melaiuauthor=M.+Minaauthor=M.+Chiericiauthor=R.+Boldriniauthor=G.+Jurmanauthor=P.+Romaniaauthor=V.+D%E2%80%99Alicandroauthor=M.+C.+Benedettiauthor=A.+Castellanoauthor=T.+Liuauthor=C.+Furlanelloauthor=F.+Locatelliauthor=D.+Fruci&title=PD-L1+is+a+therapeutic+target+of+the+bromodomain+inhibitor+JQ1+and%2C+combined+with+HLA+class+I%2C+a+promising+prognostic+biomarker+in+neuroblastoma&doi=10.1158%2F1078-0432.ccr-16-2601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma</span></div><div class="casAuthors">Melaiu, Ombretta; Mina, Marco; Chierici, Marco; Boldrini, Renata; Jurman, Giuseppe; Romania, Paolo; D'Alicandro, Valerio; Benedetti, Maria C.; Castellano, Aurora; Liu, Tao; Furlanello, Cesare; Locatelli, Franco; Fruci, Doriana</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4462-4472</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This study sought to evaluate the expression of programmed cell death-ligand-1 (PD-L1) and HLA class I on neuroblastoma cells and programmed cell death-1 (PD-1) and lymphocyte activation gene 3 (LAG3) on tumor-infiltrating lymphocytes to better define patient risk stratification and understand whether this tumor may benefit from therapies targeting immune checkpoint mols.  Exptl. Design: In situ IHC staining for PD-L1, HLA class I, PD-1, and LAG3 was assessed in 77 neuroblastoma specimens, previously characterized for tumor-infiltrating T-cell d. and correlated with clin. outcome.  Surface expression of PD-L1 was evaluated by flow cytometry and IHC in neuroblastoma cell lines and tumors genetically and/or pharmacol. inhibited for MYC and MYCN.  A dataset of 477 human primary neuroblastomas from GEO and ArrayExpress databases was explored for PD-L1, MYC, and MYCN correlation.  Results: Multivariate Cox regression anal. demonstrated that the combination of PD-L1 and HLA class I tumor cell d. is a prognostic biomarker for predicting overall survival in neuroblastoma patients (P = 0.0448).  MYC and MYCN control the expression of PD-L1 in neuroblastoma cells both in vitro and in vivo.  Consistently, abundance of PD-L1 transcript correlates with MYC expression in primary neuroblastoma.  Conclusions: The combination of PD-L1 and HLA class I represents a novel prognostic biomarker for neuroblastoma.  Pharmacol. inhibition of MYCN and MYC may be exploited to target PD-L1 and restore an efficient antitumor immunity in high-risk neuroblastoma.  Clin Cancer Res; 23(15); 4462-72. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo66-oQkiUsO7Vg90H21EOLACvtfcHk0ljSQG1SoW38yA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Ghu7jN&md5=1907d6d7b9238d22e71a6e56f9ceab46</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-16-2601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-16-2601%26sid%3Dliteratum%253Aachs%26aulast%3DMelaiu%26aufirst%3DO.%26aulast%3DMina%26aufirst%3DM.%26aulast%3DChierici%26aufirst%3DM.%26aulast%3DBoldrini%26aufirst%3DR.%26aulast%3DJurman%26aufirst%3DG.%26aulast%3DRomania%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Alicandro%26aufirst%3DV.%26aulast%3DBenedetti%26aufirst%3DM.%2BC.%26aulast%3DCastellano%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DFurlanello%26aufirst%3DC.%26aulast%3DLocatelli%26aufirst%3DF.%26aulast%3DFruci%26aufirst%3DD.%26atitle%3DPD-L1%2520is%2520a%2520therapeutic%2520target%2520of%2520the%2520bromodomain%2520inhibitor%2520JQ1%2520and%252C%2520combined%2520with%2520HLA%2520class%2520I%252C%2520a%2520promising%2520prognostic%2520biomarker%2520in%2520neuroblastoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D4462%26epage%3D4472%26doi%3D10.1158%2F1078-0432.ccr-16-2601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czub, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedlar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plewka, J.</span></span> <span> </span><span class="NLM_article-title">CA-170 - a potent small-molecule PD-L1 inhibitor or not?</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2804</span>– <span class="NLM_lpage">2815</span>, <span class="refDoi"> DOI: 10.3390/molecules24152804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.3390%2Fmolecules24152804" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=2804-2815&author=B.+Musielakauthor=J.+Kocikauthor=L.+Skalniakauthor=K.+Magiera-Mularzauthor=D.+Salaauthor=M.+Czubauthor=M.+Stecauthor=M.+Siedlarauthor=T.+A.+Holakauthor=J.+Plewka&title=CA-170+-+a+potent+small-molecule+PD-L1+inhibitor+or+not%3F&doi=10.3390%2Fmolecules24152804"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24152804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24152804%26sid%3Dliteratum%253Aachs%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSala%26aufirst%3DD.%26aulast%3DCzub%26aufirst%3DM.%26aulast%3DStec%26aufirst%3DM.%26aulast%3DSiedlar%26aufirst%3DM.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DPlewka%26aufirst%3DJ.%26atitle%3DCA-170%2520-%2520a%2520potent%2520small-molecule%2520PD-L1%2520inhibitor%2520or%2520not%253F%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D2804%26epage%3D2815%26doi%3D10.3390%2Fmolecules24152804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodovych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7250</span>– <span class="NLM_lpage">7263</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7250-7263&author=S.+Basuauthor=J.+Yangauthor=B.+Xuauthor=K.+Magiera-Mularzauthor=L.+Skalniakauthor=B.+Musielakauthor=V.+Kholodovychauthor=T.+A.+Holakauthor=L.+Hu&title=Design%2C+synthesis%2C+evaluation%2C+and+structural+studies+of+C2-symmetric+small+molecule+inhibitors+of+programmed+cell+death-1%2Fprogrammed+death-ligand+1+protein-protein+interaction&doi=10.1021%2Facs.jmedchem.9b00795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction</span></div><div class="casAuthors">Basu, Subhadwip; Yang, Jeffrey; Xu, Bin; Magiera-Mularz, Katarzyna; Skalniak, Lukasz; Musielak, Bogdan; Kholodovych, Vladyslav; Holak, Tad A.; Hu, Longqin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7250-7263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of C2-sym. inhibitors was designed and evaluated for inhibitory activity against the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein interaction (PPI) in a homogeneous time-resolved fluorescence (HTRF) assay and PD-1 signaling in cell-based coculture assays.  C2-sym. inhibitors 2a (LH1306) and 2b (LH1307) exhibited IC50 values of 25 and 3.0 nM, resp., in the HTRF assay.  While 2a was ∼3.8-fold more potent than previously reported inhibitor 1a, 2b could not be differentiated from 1b due to their high potency and the limit of our HTRF assay conditions.  In one cell-based coculture PD-1 signaling assay, 2a and 2b were 8.2- and 2.8-fold more potent in inhibiting PD-1 signaling than 1a and 1b, resp.  NMR and X-ray cocrystal structural studies provided more structural insights into the interaction between 2b and PD-L1; 2b binds to PD-L1 at the PD-1 binding site and induces the formation of a more sym. arranged PD-L1 homodimer than that previously reported for other inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS9fdh7FbNLLVg90H21EOLACvtfcHk0lgeLoy58f-Q1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ&md5=0dae949116a4157a281802aea6d21b6c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00795%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKholodovych%26aufirst%3DV.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DHu%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%252C%2520evaluation%252C%2520and%2520structural%2520studies%2520of%2520C2-symmetric%2520small%2520molecule%2520inhibitors%2520of%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7250%26epage%3D7263%26doi%3D10.1021%2Facs.jmedchem.9b00795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4703</span>– <span class="NLM_lpage">4715</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvV2qurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4703-4715&author=M.+Qinauthor=Q.+Caoauthor=S.+Zhengauthor=Y.+Tianauthor=H.+Zhangauthor=J.+Xieauthor=H.+Xieauthor=Y.+Liuauthor=Y.+Zhaoauthor=P.+Gong&title=Discovery+of+%5B1%2C2%2C4%5DTriazolo%5B4%2C3-a%5Dpyridines+as+Potent+Inhibitors+Targeting+the+Programmed+Cell+Death-1%2FProgrammed+Cell+Death-Ligand+1+Interaction&doi=10.1021%2Facs.jmedchem.9b00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction</span></div><div class="casAuthors">Qin, Mingze; Cao, Qi; Zheng, Shuaishuai; Tian, Ye; Zhang, Haotian; Xie, Jun; Xie, Hongbo; Liu, Yajing; Zhao, Yanfang; Gong, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4703-4715</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction using small-mol. inhibitors is an emerging immunotherapeutic approach.  A novel series of [1,2,4]triazolo[4,3-a]pyridines were designed and found to be potent inhibitors of the PD-1/PD-L1 interaction.  Among them, compd. I exhibited the most potent activity, as assessed by homogeneous time-resolved fluorescence assay, with an IC50 of 92.3 nM.  Furthermore, I dose-dependent elevated interferon-γ prodn. in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  The authors concluded that I is a promising lead compd. for the development of inhibitors of the PD-1/PD-L1 interaction.  In addn., the authors explored the structure-activity relationships of the newly synthesized [1,2,4]triazolo[4,3-a]pyridines and demonstrated that a ring fusion strategy can be employed for designing analogs of the Bristol-Myers Squibb chem. series.  These studies pave the way for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCgkEJ5SqGXLVg90H21EOLACvtfcHk0lgeLoy58f-Q1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvV2qurs%253D&md5=44d4ee689be577a86c16cc4da3edec71</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00312%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520%255B1%252C2%252C4%255DTriazolo%255B4%252C3-a%255Dpyridines%2520as%2520Potent%2520Inhibitors%2520Targeting%2520the%2520Programmed%2520Cell%2520Death-1%252FProgrammed%2520Cell%2520Death-Ligand%25201%2520Interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4703%26epage%3D4715%26doi%3D10.1021%2Facs.jmedchem.9b00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">112377</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1016%2Fj.ejmech.2020.112377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=32388281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFGisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2020&pages=112377&author=B.+Chengauthor=Y.+Renauthor=H.+Caoauthor=J.+Chen&title=Discovery+of+novel+resorcinol+diphenyl+ether-based+PROTAC-like+molecules+as+dual+inhibitors+and+degraders+of+PD-L1&doi=10.1016%2Fj.ejmech.2020.112377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1</span></div><div class="casAuthors">Cheng, Binbin; Ren, Yichang; Cao, Hao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112377</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Novel resorcinol di-Ph ether-based PROTACs (PROteolysis TArgeting Chimeras) were designed and evaluated for their inhibitory activity against the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway and their ability to degrade PD-L1 protein.  Most of the compds. displayed excellent inhibitory activities against PD-1/PD-L1, as assessed by the homogeneous time-resolved fluorescence (HTRF) binding assay, with IC50 values ranging from 25 nM to 200 nM.  Among them, compd. P22 (I) is one of the best with an IC50 value of 39.2 nM.  In addn. to inhibiting PD-1/PD-L1 interaction, P22 also significantly restored the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  Furthermore, flow cytometry (FCM) and western-blot data demonstrated that P22 could moderately reduce the protein levels of PD-L1 in a lysosome-dependent manner, which may contribute to its immune effects.  Preliminary FCM and western-blot data suggest that it is possible to build PD-L1-targeting PROTAC-like mols. based on PD-1/PD-L1 small mol. inhibitors, though these compds. showed only modest degrdn. efficiencies.  Collectively, this work suggests that P22 may serve as a starting point for exploring the degrdn. of PD-L1 by PROTAC-like strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiG4nI2klh77Vg90H21EOLACvtfcHk0lgeLoy58f-Q1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFGisLk%253D&md5=ec722d2e118668f601c0f9648e6f893b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112377%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520resorcinol%2520diphenyl%2520ether-based%2520PROTAC-like%2520molecules%2520as%2520dual%2520inhibitors%2520and%2520degraders%2520of%2520PD-L1%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D199%26spage%3D112377%26doi%3D10.1016%2Fj.ejmech.2020.112377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">111856</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1016%2Fj.ejmech.2019.111856" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=31734021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOmu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2020&pages=111856&author=M.+Qinauthor=Q.+Caoauthor=X.+Wuauthor=C.+Liuauthor=S.+Zhengauthor=H.+Xieauthor=Y.+Tianauthor=J.+Xieauthor=Y.+Zhaoauthor=Y.+Houauthor=X.+Zhangauthor=B.+Xuauthor=H.+Zhangauthor=X.+Wang&title=Discovery+of+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction+inhibitors+bearing+an+indoline+scaffold&doi=10.1016%2Fj.ejmech.2019.111856"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold</span></div><div class="casAuthors">Qin, Mingze; Cao, Qi; Wu, Xia; Liu, Chunyang; Zheng, Shuaishuai; Xie, Hongbo; Tian, Ye; Xie, Jun; Zhao, Yanfang; Hou, Yunlei; Zhang, Xian; Xu, Boxuan; Zhang, Haotian; Wang, Xiaobo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111856</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.  Here, a novel series of indoline-contg. compds. were developed, among which, A13 was identified as the most promising PD-1/PD-L1 pathway inhibitor.  At the biochem. level, A13 demonstrated strong inhibition of the PD-1/PD-L1 interaction, with an IC50 of 132.8 nM.  Notably, it exhibited outstanding immunoregulatory activity, and significantly elevated interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect.  Therefore, A13 could be employed as a suitable lead compd. for further design of non-peptide inhibitors targeting the PD-1/PD-L1 interaction.  In addn., the preliminary structure-activity relationships of these new indoline compds. were investigated in this study, providing valuable information for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7nYUI852jyLVg90H21EOLACvtfcHk0lhGd_pSzNiHXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOmu7zN&md5=b757929dd24437bb5af585e73a884a51</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111856%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%2520inhibitors%2520bearing%2520an%2520indoline%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D186%26spage%3D111856%26doi%3D10.1016%2Fj.ejmech.2019.111856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burr, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparbier, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, E. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolzenburg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgens, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassik, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neeson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voskoboinik, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapani, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. A.</span></span> <span> </span><span class="NLM_article-title">CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>549</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1038/nature23643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1038%2Fnature23643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=28813417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlGktrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=549&publication_year=2017&pages=101-105&author=M.+L.+Burrauthor=C.+E.+Sparbierauthor=Y.-C.+Chanauthor=J.+C.+Williamsonauthor=K.+Woodsauthor=P.+A.+Beavisauthor=E.+Y.+N.+Lamauthor=M.+A.+Hendersonauthor=C.+C.+Bellauthor=S.+Stolzenburgauthor=O.+Gilanauthor=S.+Bloorauthor=T.+Nooriauthor=D.+W.+Morgensauthor=M.+C.+Bassikauthor=P.+J.+Neesonauthor=A.+Behrenauthor=P.+K.+Darcyauthor=S.-J.+Dawsonauthor=I.+Voskoboinikauthor=J.+A.+Trapaniauthor=J.+Cebonauthor=P.+J.+Lehnerauthor=M.+A.+Dawson&title=CMTM6+maintains+the+expression+of+PD-L1+and+regulates+anti-tumour+immunity&doi=10.1038%2Fnature23643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity</span></div><div class="casAuthors">Burr, Marian L.; Sparbier, Christina E.; Chan, Yih-Chih; Williamson, James C.; Woods, Katherine; Beavis, Paul A.; Lam, Enid Y. N.; Henderson, Melissa A.; Bell, Charles C.; Stolzenburg, Sabine; Gilan, Omer; Bloor, Stuart; Noori, Tahereh; Morgens, David W.; Bassik, Michael C.; Neeson, Paul J.; Behren, Andreas; Darcy, Phillip K.; Dawson, Sarah-Jane; Voskoboinik, Ilia; Trapani, Joseph A.; Cebon, Jonathan; Lehner, Paul J.; Dawson, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">549</span>
        (<span class="NLM_cas:issue">7670</span>),
    <span class="NLM_cas:pages">101-105</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells exploit the expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) to subvert T-cell-mediated immunosurveillance.  The success of therapies that disrupt PD-L1-mediated tumor tolerance has highlighted the need to understand the mol. regulation of PD-L1 expression.  Here we identify the uncharacterized protein CMTM6 as a crit. regulator of PD-L1 in a broad range of cancer cells, by using a genome-wide CRISPR-Cas9 screen.  CMTM6 is a ubiquitously expressed protein that binds PD-L1 and maintains its cell surface expression.  CMTM6 is not required for PD-L1 maturation but co-localizes with PD-L1 at the plasma membrane and in recycling endosomes, where it prevents PD-L1 from being targeted for lysosome-mediated degrdn.  Using a quant. approach to profile the entire plasma membrane proteome, we find that CMTM6 displays specificity for PD-L1.  Notably, CMTM6 depletion decreases PD-L1 without compromising cell surface expression of MHC class I.  CMTM6 depletion, via the redn. of PD-L1, significantly alleviates the suppression of tumor-specific T cell activity in vitro and in vivo.  These findings provide insights into the biol. of PD-L1 regulation, identify a previously unrecognized master regulator of this crit. immune checkpoint and highlight a potential therapeutic target to overcome immune evasion by tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOaE7qlrP04LVg90H21EOLACvtfcHk0lhGd_pSzNiHXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlGktrvK&md5=c37c58dcfa75b3057fe4e9635789281d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnature23643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature23643%26sid%3Dliteratum%253Aachs%26aulast%3DBurr%26aufirst%3DM.%2BL.%26aulast%3DSparbier%26aufirst%3DC.%2BE.%26aulast%3DChan%26aufirst%3DY.-C.%26aulast%3DWilliamson%26aufirst%3DJ.%2BC.%26aulast%3DWoods%26aufirst%3DK.%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DLam%26aufirst%3DE.%2BY.%2BN.%26aulast%3DHenderson%26aufirst%3DM.%2BA.%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DStolzenburg%26aufirst%3DS.%26aulast%3DGilan%26aufirst%3DO.%26aulast%3DBloor%26aufirst%3DS.%26aulast%3DNoori%26aufirst%3DT.%26aulast%3DMorgens%26aufirst%3DD.%2BW.%26aulast%3DBassik%26aufirst%3DM.%2BC.%26aulast%3DNeeson%26aufirst%3DP.%2BJ.%26aulast%3DBehren%26aufirst%3DA.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DDawson%26aufirst%3DS.-J.%26aulast%3DVoskoboinik%26aufirst%3DI.%26aulast%3DTrapani%26aufirst%3DJ.%2BA.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DLehner%26aufirst%3DP.%2BJ.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26atitle%3DCMTM6%2520maintains%2520the%2520expression%2520of%2520PD-L1%2520and%2520regulates%2520anti-tumour%2520immunity%26jtitle%3DNature%26date%3D2017%26volume%3D549%26spage%3D101%26epage%3D105%26doi%3D10.1038%2Fnature23643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span> <span> </span><span class="NLM_article-title">In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>629</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1016/bs.mie.2019.05.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1016%2Fbs.mie.2019.05.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=31727249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVyrt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=629&publication_year=2019&pages=361-381&author=W.+Zhaiauthor=X.+Zhouauthor=J.+Duauthor=Y.+Gao&title=In+vitro+assay+for+the+development+of+small+molecule+inhibitors+targeting+PD-1%2FPD-L1&doi=10.1016%2Fbs.mie.2019.05.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1</span></div><div class="casAuthors">Zhai, Wenjie; Zhou, Xiuman; Du, Jiangfeng; Gao, Yanfeng</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">629</span>
        (<span class="NLM_cas:issue">Tumor Immunology and Immunotherapy: Molecular Methods</span>),
    <span class="NLM_cas:pages">361-381</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cancer immunotherapy has recently emerged as one of the hot research field since clin. successes achieved by antibody drugs of immune checkpoints, among which PD-1 and its ligand PD-L1 are the well established mols.  PD-1/PD-L1 pathway induces immune tolerance and immune evasion, esp. in tumor microenvironment, cancer cell is capable to escape the immune surveillance by up-regulating the expression level of PD-1 or PD-L1.  Blockade of PD-1/PD-L1 can unleash the anti-tumor activity, and the strategy shows great successes in the treatment of various cancer types in the late stage.  Beside antibody drugs, many other mols. such as peptides, high affinity PD(L)-1 mutants, chem. compds., and DNA aptamers are designed for inhibitors of PD-1/PD-L1 pathway.  Each modulators show their pros and cons based on their own physiochem. properties.  Here we introduced the methods for identifying low mol. wt. inhibitors of PD-1/PD-L1 and mainly discussed the cell-based blocking test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpciI296XaTR7Vg90H21EOLACvtfcHk0lhGd_pSzNiHXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVyrt7fM&md5=29aae0a76aecb165f5a5a28835f68845</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fbs.mie.2019.05.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.mie.2019.05.051%26sid%3Dliteratum%253Aachs%26aulast%3DZhai%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DY.%26atitle%3DIn%2520vitro%2520assay%2520for%2520the%2520development%2520of%2520small%2520molecule%2520inhibitors%2520targeting%2520PD-1%252FPD-L1%26jtitle%3DMethods%2520Enzymol.%26date%3D2019%26volume%3D629%26spage%3D361%26epage%3D381%26doi%3D10.1016%2Fbs.mie.2019.05.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a chiral fluorinated azetidin-2-one as a tubulin polymerisation inhibitor with potent antitumour efficacy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">112323</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1016%2Fj.ejmech.2020.112323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=32339854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVSqsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2020&pages=112323&author=H.+Tangauthor=J.+Chengauthor=Y.+Liangauthor=Y.+Wang&title=Discovery+of+a+chiral+fluorinated+azetidin-2-one+as+a+tubulin+polymerisation+inhibitor+with+potent+antitumour+efficacy&doi=10.1016%2Fj.ejmech.2020.112323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a chiral fluorinated azetidin-2-one as a tubulin polymerisation inhibitor with potent antitumour efficacy</span></div><div class="casAuthors">Tang, Hairong; Cheng, Jiayi; Liang, Yuru; Wang, Yang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112323</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Inhibition of tubulin polymn. with small mols. has been clin. validated as a promising therapy for multiple solid tumors.  Herein, a series of chiral azetidin-2-ones were asym. synthesized and biol. evaluated for antitumor activities.  Among them, a chiral fluorinated azetidin-2-one, I, was found to exhibit the most potent activities against five cancer cell lines, including a drug-resistant cell line, with IC50 values ranging from 1.0 to 3.6 nM.  Further mechanistic studies revealed that the compd. I worked by disrupting tubulin polymn., blocking the cell cycle in the G2/M phase, inducing cellular apoptosis, and suppressing angiogenesis.  Addnl., I exhibited higher human-microsomal metabolic stability and aq. soly. compared to those of combretastatin A-4.  Finally, I was also found to effectively inhibit tumor growth in a xenograft mice model with low toxicity and thus might be a promising lead for further clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDnSPTbEHXcLVg90H21EOLACvtfcHk0liw3NM9An6fCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVSqsb4%253D&md5=8e300a8fc60719d2f0732444ed959c4f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112323%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520chiral%2520fluorinated%2520azetidin-2-one%2520as%2520a%2520tubulin%2520polymerisation%2520inhibitor%2520with%2520potent%2520antitumour%2520efficacy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D197%26spage%3D112323%26doi%3D10.1016%2Fj.ejmech.2020.112323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel resorcinol dibenzyl ethers targeting the programmed cell death-1/programmed cell death-ligand 1 interaction as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8338</span>– <span class="NLM_lpage">8358</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00574</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00574" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8338-8358&author=B.+Chengauthor=Y.+Renauthor=X.+Niuauthor=W.+Wangauthor=S.+Wangauthor=Y.+Tuauthor=S.+Liuauthor=J.+Wangauthor=D.+Yangauthor=G.+Liaoauthor=J.+Chen&title=Discovery+of+novel+resorcinol+dibenzyl+ethers+targeting+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction+as+potential+anticancer+agents&doi=10.1021%2Facs.jmedchem.0c00574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents</span></div><div class="casAuthors">Cheng, Binbin; Ren, Yichang; Niu, Xiaoge; Wang, Wei; Wang, Shuanghu; Tu, Yingfeng; Liu, Shuwen; Wang, Jin; Yang, Deying; Liao, Guochao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8338-8358</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel small mol. compds. based on various scaffolds including chalcone, flavonoid, and resorcinol dibenzyl ether were designed and tested for their inhibitory activity against the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) pathway.  Among them, compd. NP19(I) inhibited the human PD-1/PD-L1 interaction with IC50 values of 12.5 nM in homogeneous time-resolved fluorescence (HTRF) binding assays.  In addn., NP19 dose-dependently elevated IFN-γ prodn. in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  Furthermore, NP19 displayed significant in vivo antitumor efficacy in two different mouse models of cancer (a melanoma B16-F10 tumor model and an H22 hepatoma tumor model).  Moreover, H&E staining and flow cytometry data suggested that NP19 activated the immune microenvironment in the tumor, which may contribute to its antitumor effects.  This work shows NP19 is a promising lead compd. for further development as a new generation of small mol. inhibitors targeting the PD-1/PD-L1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruD5Zp9HM0jrVg90H21EOLACvtfcHk0liw3NM9An6fCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsrfL&md5=a1f6b3b4c440a7152ed8194ad842370f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00574%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520resorcinol%2520dibenzyl%2520ethers%2520targeting%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8338%26epage%3D8358%26doi%3D10.1021%2Facs.jmedchem.0c00574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chow, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozga, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servis, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boland, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luster, A. D.</span></span> <span> </span><span class="NLM_article-title">Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1498</span>– <span class="NLM_lpage">1512</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2019.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1016%2Fj.immuni.2019.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=31097342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlygt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=1498-1512&author=M.+T.+Chowauthor=A.+J.+Ozgaauthor=R.+L.+Servisauthor=D.+T.+Frederickauthor=J.+A.+Loauthor=D.+E.+Fisherauthor=G.+J.+Freemanauthor=G.+M.+Bolandauthor=A.+D.+Luster&title=Intratumoral+activity+of+the+CXCR3+chemokine+system+is+required+for+the+efficacy+of+anti-PD-1+therapy&doi=10.1016%2Fj.immuni.2019.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy</span></div><div class="casAuthors">Chow, Melvyn T.; Ozga, Aleksandra J.; Servis, Rachel L.; Frederick, Dennie T.; Lo, Jennifer A.; Fisher, David E.; Freeman, Gordon J.; Boland, Genevieve M.; Luster, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1498-1512.e5</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Despite compelling rates of durable clin. responses to programmed cell death-1 (PD-1) blockade, advances are needed to extend these benefits to resistant tumors.  We found that tumor-bearing mice deficient in the chemokine receptor CXCR3 responded poorly to anti-PD-1 treatment.  CXCR3 and its ligand CXCL9 were crit. for a productive CD8+ T cell response in tumor-bearing mice treated with anti-PD-1 but were not required for the infiltration of CD8+ T cells into tumors.  The anti-PD-1-induced anti-tumor response was facilitated by CXCL9 prodn.from intratumoral CD103+ dendritic cells, suggesting that CXCR3 facilitates dendritic cell-T cell interactions within the tumor microenvironment.  CXCR3 ligands in murine tumors and in plasma of melanoma patients were an indicator of clin. response to anti-PD-1, and their induction in non-responsive murine tumors promoted responsiveness to anti-PD-1.  Our data suggest that the CXCR3 chemokine system is a biomarker for sensitivity to PD-1 blockade and that augmenting the intratumoral function of this chemokine system could improve clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSw41CZG6jOLVg90H21EOLACvtfcHk0liw3NM9An6fCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlygt7o%253D&md5=2244962249d55dcc7ad6c3dbdac81955</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2019.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2019.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DChow%26aufirst%3DM.%2BT.%26aulast%3DOzga%26aufirst%3DA.%2BJ.%26aulast%3DServis%26aufirst%3DR.%2BL.%26aulast%3DFrederick%26aufirst%3DD.%2BT.%26aulast%3DLo%26aufirst%3DJ.%2BA.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DBoland%26aufirst%3DG.%2BM.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26atitle%3DIntratumoral%2520activity%2520of%2520the%2520CXCR3%2520chemokine%2520system%2520is%2520required%2520for%2520the%2520efficacy%2520of%2520anti-PD-1%2520therapy%26jtitle%3DImmunity%26date%3D2019%26volume%3D50%26spage%3D1498%26epage%3D1512%26doi%3D10.1016%2Fj.immuni.2019.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juneja, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manguso, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFleur, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haining, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">904</span>, <span class="refDoi"> DOI: 10.1084/jem.20160801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1084%2Fjem.20160801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=28302645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2ju7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2017&pages=895-904&author=V.+R.+Junejaauthor=K.+A.+McGuireauthor=R.+T.+Mangusoauthor=M.+W.+LaFleurauthor=N.+Collinsauthor=W.+N.+Hainingauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=PD-L1+on+tumor+cells+is+sufficient+for+immune+evasion+in+immunogenic+tumors+and+inhibits+CD8+T+cell+cytotoxicity&doi=10.1084%2Fjem.20160801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity</span></div><div class="casAuthors">Juneja, Vikram R.; McGuire, Kathleen A.; Manguso, Robert T.; LaFleur, Martin W.; Collins, Natalie; Haining, W. Nicholas; Freeman, Gordon J.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-904</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">It is unclear whether PD-L1 on tumor cells is sufficient for tumor immune evasion or simply correlates with an inflamed tumor microenvironment.  We used three mouse tumor models sensitive to PD-1 blockade to evaluate the significance of PD-L1 on tumor vs. nontumor cells.  PD-L1 on nontumor cells is crit. for inhibiting antitumor immunity in B16 melanoma and a genetically engineered melanoma.  In contrast, PD-L1 on MC38 colorectal adenocarcinoma cells is sufficient to suppress antitumor immunity, as deletion of PD-L1 on highly immunogenic MC38 tumor cells allows effective antitumor immunity.  MC38-derived PD-L1 potently inhibited CD8+ T cell cytotoxicity.  Wild-type MC38 cells outcompeted PD-L1-deleted MC38 cells in vivo, demonstrating tumor PD-L1 confers a selective advantage.  Thus, both tumor- and host-derived PD-L1 can play crit. roles in immunosuppression.  Differences in tumor immunogenicity appear to underlie their relative importance.  Our findings establish reduced cytotoxicity as a key mechanism by which tumor PD-L1 suppresses antitumor immunity and demonstrate that tumor PD-L1 is not just a marker of suppressed antitumor immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOvfjGoOhPg7Vg90H21EOLACvtfcHk0li8e80CUPmd9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2ju7nJ&md5=95ceac8e66dd13f327bfc0eb3dab42c1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1084%2Fjem.20160801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20160801%26sid%3Dliteratum%253Aachs%26aulast%3DJuneja%26aufirst%3DV.%2BR.%26aulast%3DMcGuire%26aufirst%3DK.%2BA.%26aulast%3DManguso%26aufirst%3DR.%2BT.%26aulast%3DLaFleur%26aufirst%3DM.%2BW.%26aulast%3DCollins%26aufirst%3DN.%26aulast%3DHaining%26aufirst%3DW.%2BN.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DPD-L1%2520on%2520tumor%2520cells%2520is%2520sufficient%2520for%2520immune%2520evasion%2520in%2520immunogenic%2520tumors%2520and%2520inhibits%2520CD8%2520T%2520cell%2520cytotoxicity%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2017%26volume%3D214%26spage%3D895%26epage%3D904%26doi%3D10.1084%2Fjem.20160801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 2 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yiqiang OuYang, Jian Gao, Lei Zhao, Junfeng Lu, Haiqing Zhong, Hua Tang, Shuanglong Jin, Lu Yue, Yuezhen Li, Wenjie Guo, Qiang Xu, <span class="NLM_string-name hlFld-ContribAuthor">Yisheng Lai</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7646-7666. <a href="https://doi.org/10.1021/acs.jmedchem.1c00370" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00370</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00370%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BEvaluation%252Bof%252Bo-%252528Biphenyl-3-ylmethoxy%252529nitrophenyl%252BDerivatives%252Bas%252BPD-1%25252FPD-L1%252BInhibitors%252Bwith%252BPotent%252BAnticancer%252BEfficacy%252BIn%252BVivo%26aulast%3DOuYang%26aufirst%3DYiqiang%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D01032021%26date%3D26052021%26volume%3D64%26issue%3D11%26spage%3D7646%26epage%3D7666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xinyan  Dai</span>, <span class="hlFld-ContribAuthor ">Ke  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Chen</span>, <span class="hlFld-ContribAuthor ">Xupeng  Huang</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of 1-methyl-1H-pyrazolo[4,3-b]pyridine derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105034. <a href="https://doi.org/10.1016/j.bioorg.2021.105034" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105034</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105034%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252B1-methyl-1H-pyrazolo%25255B4%25252C3-b%25255Dpyridine%252Bderivatives%252Bas%252Bnovel%252Bsmall-molecule%252Binhibitors%252Btargeting%252Bthe%252BPD-1%25252FPD-L1%252Binteraction%26aulast%3DDai%26aufirst%3DXinyan%26date%3D2021%26volume%3D114%26spage%3D105034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative small molecule modulators of PD-1/PD-L1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>P1–18</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reaction conditions: (a) NaHCO<sub>3</sub>, anhydrous DMF, 60 °C, 2 h, and 40%; (b) Na<sub>2</sub>CO<sub>3</sub>, anhydrous DMF, 80 °C, 0.5 h, and 60%; (c) Pd(PPh<sub>3</sub>)<sub>4</sub>, DMSO/H<sub>2</sub>O = 10/1, 100 °C, 12 h, and 25–30%; (d) NaBH<sub>3</sub>CN, anhydrous DMF, glacial acetic acid, 80 °C, 2 h, and 15–25%; (e) (i) HATU, DIPEA, DMF, rt, 1 h, and 70–80%; and (ii) 4 M HCl in 1,4-dioxane, DCM, 0 °C, 2 h, and 80–90%.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Docking analysis of compound <b>P18</b> in the hydrophobic binding interface of PD-L1 and (B) orientation of compound <b>P18</b> in the binding interface of the PD-L1 dimer (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIU">5NIU</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Effects of compounds <b>P11</b>, <b>P18</b>, and BMS-202 on the mortality rate of HepG2 cells in a HepG2/Jurkat coculture coculture cell model. Data are presented as mean ± SD, **<i>P</i> < 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Real-time interaction between human PD-L1 and compound <b>P18</b> (A) and murine PD-L1 and compound <b>P18</b> (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Circular dichroism spectra of human PD-L1 in complex with compound <b>P18</b> and (B) CD spectra of murine PD-L1 in complex with compound <b>P18</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Therapeutic effects of compound <b>P18</b> on a human PD-1 knock-in tumor mouse model. (A) Image of tumors; (B) tumor weights; (C) tumor volume; (D) body weight changes; (E) spleen weight; and (F) thymus weight. [**<i>P</i> < 0.05 <i>vs</i> vehicle control, <i>n</i> = 5, one-way analysis of variance (ANOVA).]</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Quantitative RT-PCR analysis of the mRNA expression for CXCR3, CXCL9, CXCL10, and PD-L1 in melanoma tumors. (A) Relative expression of CXCR3 mRNA; (B) relative expression of CXCL9 mRNA; (C) relative expression of CXCL10 mRNA; and (D) relative expression of PD-L1 mRNA. (**<i>P</i> < 0.05, <i>n</i> = 5, one-way ANOVA.)</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Percentages of TILs (CD3<sup>+</sup>CD4<sup>+</sup> cells and CD3<sup>+</sup>CD8<sup>+</sup> cells) in spleen and/or tumor tissues of melanoma-bearing human PD-1 knock-in mice (vehicle control group vs <b>P18</b>-treated groups). (A) Representative examples for TILs in melanoma tumors; (B) representative examples for TILs in spleen; (C) CD3<sup>+</sup>CD4<sup>+</sup> cells in melanoma tumors (<i>n</i> = 5); (D) CD3<sup>+</sup>CD8<sup>+</sup> cells in melanoma tumors (<i>n</i> = 5); (E) spleen CD3<sup>+</sup>CD4<sup>+</sup> cells (<i>n</i> = 5); (F) spleen CD3<sup>+</sup>CD8<sup>+</sup> cells (<i>n</i> = 5); (G) PD-L1 expression levels in melanoma tumors (<i>n</i> = 5); (H) ISO control; (I) PD-L1 expression levels in vehicle control; and (J) PD-L1 expression levels in <b>P18</b> treatment group (**<i>P</i> < 0.05, <i>n</i> = 5, one-way ANOVA).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Pathological analysis of liver and kidney tissues collected from human PD-1 knock-in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Serum biochemistry analysis (levels of kidney and liver function in human PD-1 knock-in mice): (A) TP; (B) A/G; (C) ALB; (D) ALT; (E) CRE; (F) GGT; (G) GLO; (H) GLU; (I) UREA; (J) AST; and (K) TBIL. Mean ± SD. <i>P</i> values were analyzed by one-way ANOVA with the vehicle control as the comparison.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/medium/jm0c01684_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Evaluation of <i>in vivo</i> cardiotoxicity and myelosuppression of <b>P18</b> by EGC and blood cell analysis in BALB/c mice. (A) Control group (0.9% saline solution); (B) <b>P18</b> at 100 mg/kg; (C) <b>P18</b> at 50 mg/kg; and (D) blood cell analysis.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-24/acs.jmedchem.0c01684/20201218/images/large/jm0c01684_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01684&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i67">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83410" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83410" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 19 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shekarian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valsesia-Wittmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marabelle, A.</span></span> <span> </span><span class="NLM_article-title">Paradigm shift in oncology: targeting the immune system rather than cancer cells</span>. <i>Mutagenesis</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">205</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1093/mutage/geu073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1093%2Fmutage%2Fgeu073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=25688113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlaqs73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2015&pages=205-211&author=T.+Shekarianauthor=S.+Valsesia-Wittmannauthor=C.+Cauxauthor=A.+Marabelle&title=Paradigm+shift+in+oncology%3A+targeting+the+immune+system+rather+than+cancer+cells&doi=10.1093%2Fmutage%2Fgeu073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Paradigm shift in oncology: targeting the immune system rather than cancer cells</span></div><div class="casAuthors">Shekarian, Tala; Valsesia-Wittmann, Sandrine; Caux, Christophe; Marabelle, Aurelien</div><div class="citationInfo"><span class="NLM_cas:title">Mutagenesis</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">205-211</span>CODEN:
                <span class="NLM_cas:coden">MUTAEX</span>;
        ISSN:<span class="NLM_cas:issn">0267-8357</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The clin. benefits obtained with rituximab in the treatment of CD20+ B-cell malignancies and of imatinib in the treatment of Phi+ leukemias have opened a new era in oncol., transforming the concepts of tumor-targeted therapies and personalised medicine into reality.  Since then, many tumor-targeted monoclonal antibodies and tyrosine kinase inhibitors have been approved for the treatment of cancers.  Compared to conventional chemotherapies, these new drugs have more specificity against cancer cells and less systemic toxicities.  However, like conventional chemotherapies, they often provide limited therapeutic benefits with short-lasting tumor responses as the vast majority of cancers become resistant to these drugs over time.  Therefore, tumor-targeted therapies are an incremental innovation as compared to historical chemotherapies.  Recently, a paradigm shift has been brought to the clinic with drugs targeting immune cells rather than cancer cells with the aim of stimulating the anti-tumor immune response of patients against their own cancer.  Immunomodulatory drugs such as anti-CTLA4 and anti-PD-1 have generated long-lasting tumor responses when used as single agent in patients with refractory/relapsing cancers such as metastatic melanomas, renal cell carcinoma or non-small-cell lung carcinoma.  These new immune-targeted therapies are therefore a disruptive innovation in cancer treatment: they demonstrate that long-lasting clin. benefits could be obtained by targeting mols. involved in the immune tolerance of cancer cells rather than by targeting oncogenic drivers or antigens expressed by cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIgftDslSuLbVg90H21EOLACvtfcHk0lgY-78anxCt0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlaqs73L&md5=ca56e09fd20963569e1829a8c91d7759</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1093%2Fmutage%2Fgeu073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fmutage%252Fgeu073%26sid%3Dliteratum%253Aachs%26aulast%3DShekarian%26aufirst%3DT.%26aulast%3DValsesia-Wittmann%26aufirst%3DS.%26aulast%3DCaux%26aufirst%3DC.%26aulast%3DMarabelle%26aufirst%3DA.%26atitle%3DParadigm%2520shift%2520in%2520oncology%253A%2520targeting%2520the%2520immune%2520system%2520rather%2520than%2520cancer%2520cells%26jtitle%3DMutagenesis%26date%3D2015%26volume%3D30%26spage%3D205%26epage%3D211%26doi%3D10.1093%2Fmutage%2Fgeu073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanmeerbeek, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprooten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ruysscher, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tejpar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandenberghe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fucikova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spisek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zitvogel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroemer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galluzzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, A. D.</span></span> <span> </span><span class="NLM_article-title">Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology</span>. <i>Oncoimmunology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1703449</span>, <span class="refDoi"> DOI: 10.1080/2162402X.2019.1703449</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1080%2F2162402X.2019.1703449" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=32002302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVOgsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=1703449&author=I.+Vanmeerbeekauthor=J.+Sprootenauthor=D.+De+Ruysscherauthor=S.+Tejparauthor=P.+Vandenbergheauthor=J.+Fucikovaauthor=R.+Spisekauthor=L.+Zitvogelauthor=G.+Kroemerauthor=L.+Galluzziauthor=A.+D.+Garg&title=Trial+watch%3A+chemotherapy-induced+immunogenic+cell+death+in+immuno-oncology&doi=10.1080%2F2162402X.2019.1703449"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology</span></div><div class="casAuthors">Vanmeerbeek, Isaure; Sprooten, Jenny; De Ruysscher, Dirk; Tejpar, Sabine; Vandenberghe, Peter; Fucikova, Jitka; Spisek, Radek; Zitvogel, Laurence; Kroemer, Guido; Galluzzi, Lorenzo; Garg, Abhishek D.</div><div class="citationInfo"><span class="NLM_cas:title">OncoImmunology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1703449/1-1703449/24</span>CODEN:
                <span class="NLM_cas:coden">ONCOGX</span>;
        ISSN:<span class="NLM_cas:issn">2162-402X</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  The term 'immunogenic cell death' (ICD) denotes an immunol. unique type of regulated cell death that enables, rather than suppresses, T cell-driven immune responses that are specific for antigens derived from the dying cells.  The ability of ICD to elicit adaptive immunity heavily relies on the immunogenicity of dying cells, implying that such cells must encode and present antigens not covered by central tolerance (antigenicity), and deliver immunostimulatory mols. such as damage-assocd. mol. patterns and cytokines (adjuvanticity).  Moreover, the host immune system must be equipped to detect the antigenicity and adjuvanticity of dying cells.  As cancer (but not normal) cells express several antigens not covered by central tolerance, they can be driven into ICD by some therapeutic agents, including (but not limited to) chemotherapeutics of the anthracycline family, oxaliplatin and bortezomib, as well as radiation therapy.  In this Trial Watch, we describe current trends in the preclin. and clin. development of ICD-eliciting chemotherapy as partner for immunotherapy, with a focus on trials assessing efficacy in the context of immunomonitoring.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGNLShZG_SZLVg90H21EOLACvtfcHk0lgY-78anxCt0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVOgsQ%253D%253D&md5=207cf4aab92fe3a45b7477fb0bb5e870</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1080%2F2162402X.2019.1703449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F2162402X.2019.1703449%26sid%3Dliteratum%253Aachs%26aulast%3DVanmeerbeek%26aufirst%3DI.%26aulast%3DSprooten%26aufirst%3DJ.%26aulast%3DDe%2BRuysscher%26aufirst%3DD.%26aulast%3DTejpar%26aufirst%3DS.%26aulast%3DVandenberghe%26aufirst%3DP.%26aulast%3DFucikova%26aufirst%3DJ.%26aulast%3DSpisek%26aufirst%3DR.%26aulast%3DZitvogel%26aufirst%3DL.%26aulast%3DKroemer%26aufirst%3DG.%26aulast%3DGalluzzi%26aufirst%3DL.%26aulast%3DGarg%26aufirst%3DA.%2BD.%26atitle%3DTrial%2520watch%253A%2520chemotherapy-induced%2520immunogenic%2520cell%2520death%2520in%2520immuno-oncology%26jtitle%3DOncoimmunology%26date%3D2020%26volume%3D9%26spage%3D1703449%26doi%3D10.1080%2F2162402X.2019.1703449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betof, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dearden, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rapazzo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valentine, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brohl, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ancell, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menzies, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eroglu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoushtari, A. N.</span></span> <span> </span><span class="NLM_article-title">Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1093%2Fannonc%2Fmdx642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=29045547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A280%3ADC%252BC1M7itVCltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=250-255&author=M.+H.+Pollackauthor=A.+Betofauthor=H.+Deardenauthor=K.+Rapazzoauthor=I.+Valentineauthor=A.+S.+Brohlauthor=K.+K.+Ancellauthor=G.+V.+Longauthor=A.+M.+Menziesauthor=Z.+Erogluauthor=D.+B.+Johnsonauthor=A.+N.+Shoushtari&title=Safety+of+resuming+anti-PD-1+in+patients+with+immune-related+adverse+events+%28irAEs%29+during+combined+anti-CTLA-4+and+anti-PD1+in+metastatic+melanoma&doi=10.1093%2Fannonc%2Fmdx642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma</span></div><div class="casAuthors">Pollack M H; Pollack M H; Betof A; Shoushtari A N; Dearden H; Long G V; Menzies A M; Rapazzo K; Ancell K K; Johnson D B; Rapazzo K; Ancell K K; Johnson D B; Valentine I; Brohl A S; Eroglu Z; Long G V; Menzies A M; Long G V; Menzies A M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">250-255</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Combined cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) blockade induces high rates of immune-related adverse events (irAEs).  The safety of resuming anti-PD-1 in patients who discontinue combination therapy due to irAEs is not known.  Patients and methods:  We assessed patients who experienced clinically significant irAEs from combined CTLA-4 and PD-1 blockade leading to treatment discontinuation at four academic centers.  We assessed the safety of resuming anti-PD-1 in terms of recurrent and distinct irAEs.  Results:  Eighty patients discontinued combination therapy due to irAEs, including colitis (41%), hepatitis (36%), and pneumonitis (4%).  Of these, 96% received corticosteroids and 21% received additional immunosuppression (e.g. infliximab).  All were rechallenged with anti-PD-1, and 14 (18%) had recurrent irAEs at a median of 14 days after therapy resumption (six grade 1-2, seven grade 3-4, and one grade 5 Steven-Johnson Syndrome).  Colitis was less likely to recur than other irAEs (6% versus 28%, P = 0.01).  Clinically significant but distinct toxicities occurred in an additional 17 (21%) patients (11 grade 1-2 and 6 grade 3-4).  Duration of steroid taper, severity of initial irAEs and use of additional immunosuppressants did not predict for toxicity on rechallenge, although patients remaining on steroid therapy at anti-PD-1 resumption had higher rates of toxicities (55% versus 31%, P = 0.03).  Conclusions:  Patients who discontinued CTLA-4/PD-1 blockade for severe irAEs had relatively high rates of recurrent or distinct toxicities with anti-PD-1 resumption.  However, many patients, particularly with combination-induced colitis, tolerated anti-PD-1 rechallenge well, and this approach can be considered in selected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqAkqru7T6kdXdcedVHT5tfW6udTcc2eYOcNf3XfCChLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7itVCltA%253D%253D&md5=39b9a61c164e6d6b1eb7fb1210c3cd24</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx642%26sid%3Dliteratum%253Aachs%26aulast%3DPollack%26aufirst%3DM.%2BH.%26aulast%3DBetof%26aufirst%3DA.%26aulast%3DDearden%26aufirst%3DH.%26aulast%3DRapazzo%26aufirst%3DK.%26aulast%3DValentine%26aufirst%3DI.%26aulast%3DBrohl%26aufirst%3DA.%2BS.%26aulast%3DAncell%26aufirst%3DK.%2BK.%26aulast%3DLong%26aufirst%3DG.%2BV.%26aulast%3DMenzies%26aufirst%3DA.%2BM.%26aulast%3DEroglu%26aufirst%3DZ.%26aulast%3DJohnson%26aufirst%3DD.%2BB.%26aulast%3DShoushtari%26aufirst%3DA.%2BN.%26atitle%3DSafety%2520of%2520resuming%2520anti-PD-1%2520in%2520patients%2520with%2520immune-related%2520adverse%2520events%2520%2528irAEs%2529%2520during%2520combined%2520anti-CTLA-4%2520and%2520anti-PD1%2520in%2520metastatic%2520melanoma%26jtitle%3DAnn.%2520Oncol.%26date%3D2018%26volume%3D29%26spage%3D250%26epage%3D255%26doi%3D10.1093%2Fannonc%2Fmdx642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, A.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">180</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.2174/1568026619666190308131805</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.2174%2F1568026619666190308131805" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=30854972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVGhtL7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=180-185&author=S.+Chenauthor=Z.+Songauthor=A.+Zhang&title=Small-Molecule+Immuno-Oncology+Therapy%3A+Advances%2C+Challenges+and+New+Directions&doi=10.2174%2F1568026619666190308131805"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Immuno-Oncology Therapy: Advances, Challenges and New Directions</span></div><div class="casAuthors">Chen, Shulun; Song, Zilan; Zhang, Ao</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">180-185</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Oncol. immunotherapy has gained significant advances in recent years and benefits cancer patients with superior efficacy and superior clin. responses.  Currently over ten immune checkpoint antibodies targeting CTLA-4 and PD-1/PD-L1 have received regulatory approval worldwide and over thousands are under active clin. trials.  However, compared to the rapid advance of Monoclonal Antibody (mAb), studies on immunotherapeutic small mols. have far lagged behind.  Small mol. immunotherapy not only can target immunosuppressive mechanisms similar to mAbs, but also can stimulate intracellular pathways downstream of checkpoint proteins in innate or adaptive immune cells that mAbs are unable to access.  Therefore, small mol. immunotherapy can provide an alternative treatment modality either alone or complementary to or synergistic with extracellular checkpoint mAbs to address low clin. response and drug resistance.  Fortunately, remarkable progress has achieved recently in the pursuit of small mol. immunotherapy.  This review intends to provide a timely highlight on those clin. investigated small mols. targeting PD-1/PD-L1, IDO1, and STING.  The most advanced IDO1 inhibitor epacadostat have been aggressively progressed into multiple clin. testings.  Small mol. PD-1/PD-L1 inhibitors and STING activators are still in a premature state and their decisive application needs to wait for the ongoing clin. outcomes.  Since no small mol. immunotherapy has been approved yet, the future research should continue to focus on discovery of novel small mols. with distinct chemo-types and higher potency, identification of biomarkers to precisely stratify patients, as well as validation of many other immune-therapeutic targets, such as LAG3, KIRs, TIM-3, VISTA, B7-H3, and TIGIT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIg_rDysKA6LVg90H21EOLACvtfcHk0ljjUXKq8MAzHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVGhtL7E&md5=944b0fc0de82574b1a24f3e910eaccf4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190308131805&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190308131805%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DA.%26atitle%3DSmall-Molecule%2520Immuno-Oncology%2520Therapy%253A%2520Advances%252C%2520Challenges%2520and%2520New%2520Directions%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D180%26epage%3D185%26doi%3D10.2174%2F1568026619666190308131805" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, W.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Recent advances in small molecule based cancer immunotherapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">582</span>– <span class="NLM_lpage">598</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1016%2Fj.ejmech.2018.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=30125720" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=582-598&author=B.+Chengauthor=W.-E.+Yuanauthor=J.+Suauthor=Y.+Liuauthor=J.+Chen&title=Recent+advances+in+small+molecule+based+cancer+immunotherapy&doi=10.1016%2Fj.ejmech.2018.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in small molecule based cancer immunotherapy</span></div><div class="casAuthors">Cheng, Binbin; Yuan, Wei-En; Su, Jing; Liu, Yao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">582-598</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Immunotherapy has been increasingly utilized for the treatment of cancer.  Currently available cancer immunotherapies mainly involve the use of antibodies, which have advantages in terms of pharmacodynamics such as efficacy and specificity, however, they exhibit disadvantages in regard to the pharmacokinetics including but not limited to poor tissue and tumor penetration, very long half-life, and the lack of oral bioavailability.  Also they are immunogenic and may cause undesired side effects.  In addn., they are difficult and expensive to produce.  In contrast to therapeutic antibodies, small mol. immuno-oncol. agents generally have favorable pharmacokinetics, for example, better oral bioavailability, higher tissue and tumor penetration, reasonable half-lives etc.  Furthermore, some small mols. are highly selective and efficacious with benign toxicity profiles.  Therefore, small mol. immuno-oncol. agents have the potential to overcome the drawbacks of therapeutic antibodies, and they can complement existing therapeutic antibodies and may also be used in combination with antibodies to achieve synergistic effects.  In this article, we summarize the current advances in the field of small mol. approaches in tumor immunol. which include the small mols. in clin. trials and preclin. studies, and the reported crystal structures of small mols. and their target proteins as well as the binding interactions between small mols. and the targets.  The tumorigenesis mechanism of different targets (the programmed cell death 1/programmed cell death ligand 1(PD1/PD-L1), retinoic acid-related orphan receptor-gamma t (RORγt), Chemokine receptor, Stimulator of Interferon Genes (Sting), Indoleamine 2,3-dioxygenase (IDO), toll-like receptors (TLR) etc.) are also elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvYDM1Fp9HUbVg90H21EOLACvtfcHk0ljjUXKq8MAzHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFOqsb%252FP&md5=e15fa8048cf9b12ecd494d9ff8db8be5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DYuan%26aufirst%3DW.-E.%26aulast%3DSu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DRecent%2520advances%2520in%2520small%2520molecule%2520based%2520cancer%2520immunotherapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D582%26epage%3D598%26doi%3D10.1016%2Fj.ejmech.2018.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sasikumar, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Small-molecule immune checkpoint inhibitors targeting PD-1/PD-L1 and other emerging checkpoint pathways</span>. <i>BioDrugs</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">497</span>, <span class="refDoi"> DOI: 10.1007/s40259-018-0303-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1007%2Fs40259-018-0303-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=30168070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs1Wkt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=481-497&author=P.+G.+Sasikumarauthor=M.+Ramachandra&title=Small-molecule+immune+checkpoint+inhibitors+targeting+PD-1%2FPD-L1+and+other+emerging+checkpoint+pathways&doi=10.1007%2Fs40259-018-0303-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways</span></div><div class="casAuthors">Sasikumar, Pottayil G.; Ramachandra, Murali</div><div class="citationInfo"><span class="NLM_cas:title">BioDrugs</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">481-497</span>CODEN:
                <span class="NLM_cas:coden">BIDRF4</span>;
        ISSN:<span class="NLM_cas:issn">1173-8804</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Advances in harnessing the immune system for cancer treatment have been spectacular in recent years as witnessed by the approval of a no. of antibodies targeting the PD-1/PD-L1 immune checkpoint pathway spanning an expanding list of indications.  However, it is well recognized that while these antibodies show impressive clin. activity, they suffer from shortcomings including the failure to show response in a majority of patients, their need to be administered by i.v. injection, and immune-related adverse events due to the breaking of immune self-tolerance.  Small-mol.-based therapeutic approaches offer the potential to address the shortcomings of these antibody-based checkpoint inhibitors.  In the first part of this review, we discuss the rationale for small-mol.-based checkpoint therapy followed by efforts on the discovery of small-mol.-based approaches targeting the PD-1/PD-L1 axis and other immune checkpoint pathways.  In the latter part of the article, we describe small-mol. inhibitors simultaneously targeting two non-redundant checkpoint inhibitor pathways as an approach to improve the response rate.  A brief review of the progress of an oral small-mol. checkpoint inhibitor currently in clin. development is presented at the end.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojNSkErWJotrVg90H21EOLACvtfcHk0ljan443QHHO9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs1Wkt7rM&md5=9c411ae13233e05057b9b3e4a014a7ee</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs40259-018-0303-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40259-018-0303-4%26sid%3Dliteratum%253Aachs%26aulast%3DSasikumar%26aufirst%3DP.%2BG.%26aulast%3DRamachandra%26aufirst%3DM.%26atitle%3DSmall-molecule%2520immune%2520checkpoint%2520inhibitors%2520targeting%2520PD-1%252FPD-L1%2520and%2520other%2520emerging%2520checkpoint%2520pathways%26jtitle%3DBioDrugs%26date%3D2018%26volume%3D32%26spage%3D481%26epage%3D497%26doi%3D10.1007%2Fs40259-018-0303-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guzik, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zak, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grudnik, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Törner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dömling, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span> <span> </span><span class="NLM_article-title">Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">5857</span>– <span class="NLM_lpage">5867</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00293</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00293" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFeisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=5857-5867&author=K.+Guzikauthor=K.+M.+Zakauthor=P.+Grudnikauthor=K.+Magieraauthor=B.+Musielakauthor=R.+T%C3%B6rnerauthor=L.+Skalniakauthor=A.+D%C3%B6mlingauthor=G.+Dubinauthor=T.+A.+Holak&title=Small-molecule+inhibitors+of+the+programmed+cell+death-1%2Fprogrammed+death-ligand+1+%28PD-1%2FPD-L1%29+interaction+via+transiently+induced+protein+states+and+dimerization+of+PD-L1&doi=10.1021%2Facs.jmedchem.7b00293"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1</span></div><div class="casAuthors">Guzik, Katarzyna; Zak, Krzysztof M.; Grudnik, Przemyslaw; Magiera, Katarzyna; Musielak, Bogdan; Torner, Ricarda; Skalniak, Lukasz; Domling, Alexander; Dubin, Grzegorz; Holak, Tad A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">5857-5867</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockade of the PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provided significant advances in cancer treatment.  The antibody-based immunotherapies carry a no. of disadvantages such as the high cost of the antibodies, their limited half-life, and immunogenicity.  Development of small-mol. PD-1/PD-L1 inhibitors that could overcome these drawbacks is slow because of the incomplete structural information for this pathway.  The first chem. PD-1/PD-L1 inhibitors have been recently disclosed by Bristol-Myers Squibb.  Here we present NMR and X-ray characterization for the two classes of these inhibitors.  The X-ray structures of the PD-L1/inhibitor complexes reveal one inhibitor mol. located at the center of the PD-L1 homodimer, filling a deep hydrophobic channel-like pocket between two PD-L1 mols.  Derivs. of (2-methyl-3-biphenylyl)methanol exhibit the structures capped on one side of the channel, whereas the compds. based on [3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methylphenyl]methanol induce an enlarged interaction interface that results in the open "face-back" tunnel through the PD-L1 dimer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppmfSesG1M6rVg90H21EOLACvtfcHk0ljan443QHHO9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFeisLc%253D&md5=c039796cda3b9ef92a0ed3b10b11932b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00293&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00293%26sid%3Dliteratum%253Aachs%26aulast%3DGuzik%26aufirst%3DK.%26aulast%3DZak%26aufirst%3DK.%2BM.%26aulast%3DGrudnik%26aufirst%3DP.%26aulast%3DMagiera%26aufirst%3DK.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DT%25C3%25B6rner%26aufirst%3DR.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DD%25C3%25B6mling%26aufirst%3DA.%26aulast%3DDubin%26aufirst%3DG.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26atitle%3DSmall-molecule%2520inhibitors%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520%2528PD-1%252FPD-L1%2529%2520interaction%2520via%2520transiently%2520induced%2520protein%2520states%2520and%2520dimerization%2520of%2520PD-L1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D5857%26epage%3D5867%26doi%3D10.1021%2Facs.jmedchem.7b00293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melaiu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chierici, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boldrini, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romania, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Alicandro, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furlanello, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locatelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruci, D.</span></span> <span> </span><span class="NLM_article-title">PD-L1 is a therapeutic target of the bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4462</span>– <span class="NLM_lpage">4472</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-16-2601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1158%2F1078-0432.ccr-16-2601" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=28270499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Ghu7jN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=4462-4472&author=O.+Melaiuauthor=M.+Minaauthor=M.+Chiericiauthor=R.+Boldriniauthor=G.+Jurmanauthor=P.+Romaniaauthor=V.+D%E2%80%99Alicandroauthor=M.+C.+Benedettiauthor=A.+Castellanoauthor=T.+Liuauthor=C.+Furlanelloauthor=F.+Locatelliauthor=D.+Fruci&title=PD-L1+is+a+therapeutic+target+of+the+bromodomain+inhibitor+JQ1+and%2C+combined+with+HLA+class+I%2C+a+promising+prognostic+biomarker+in+neuroblastoma&doi=10.1158%2F1078-0432.ccr-16-2601"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma</span></div><div class="casAuthors">Melaiu, Ombretta; Mina, Marco; Chierici, Marco; Boldrini, Renata; Jurman, Giuseppe; Romania, Paolo; D'Alicandro, Valerio; Benedetti, Maria C.; Castellano, Aurora; Liu, Tao; Furlanello, Cesare; Locatelli, Franco; Fruci, Doriana</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4462-4472</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: This study sought to evaluate the expression of programmed cell death-ligand-1 (PD-L1) and HLA class I on neuroblastoma cells and programmed cell death-1 (PD-1) and lymphocyte activation gene 3 (LAG3) on tumor-infiltrating lymphocytes to better define patient risk stratification and understand whether this tumor may benefit from therapies targeting immune checkpoint mols.  Exptl. Design: In situ IHC staining for PD-L1, HLA class I, PD-1, and LAG3 was assessed in 77 neuroblastoma specimens, previously characterized for tumor-infiltrating T-cell d. and correlated with clin. outcome.  Surface expression of PD-L1 was evaluated by flow cytometry and IHC in neuroblastoma cell lines and tumors genetically and/or pharmacol. inhibited for MYC and MYCN.  A dataset of 477 human primary neuroblastomas from GEO and ArrayExpress databases was explored for PD-L1, MYC, and MYCN correlation.  Results: Multivariate Cox regression anal. demonstrated that the combination of PD-L1 and HLA class I tumor cell d. is a prognostic biomarker for predicting overall survival in neuroblastoma patients (P = 0.0448).  MYC and MYCN control the expression of PD-L1 in neuroblastoma cells both in vitro and in vivo.  Consistently, abundance of PD-L1 transcript correlates with MYC expression in primary neuroblastoma.  Conclusions: The combination of PD-L1 and HLA class I represents a novel prognostic biomarker for neuroblastoma.  Pharmacol. inhibition of MYCN and MYC may be exploited to target PD-L1 and restore an efficient antitumor immunity in high-risk neuroblastoma.  Clin Cancer Res; 23(15); 4462-72. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo66-oQkiUsO7Vg90H21EOLACvtfcHk0ljan443QHHO9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Ghu7jN&md5=1907d6d7b9238d22e71a6e56f9ceab46</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-16-2601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-16-2601%26sid%3Dliteratum%253Aachs%26aulast%3DMelaiu%26aufirst%3DO.%26aulast%3DMina%26aufirst%3DM.%26aulast%3DChierici%26aufirst%3DM.%26aulast%3DBoldrini%26aufirst%3DR.%26aulast%3DJurman%26aufirst%3DG.%26aulast%3DRomania%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Alicandro%26aufirst%3DV.%26aulast%3DBenedetti%26aufirst%3DM.%2BC.%26aulast%3DCastellano%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DFurlanello%26aufirst%3DC.%26aulast%3DLocatelli%26aufirst%3DF.%26aulast%3DFruci%26aufirst%3DD.%26atitle%3DPD-L1%2520is%2520a%2520therapeutic%2520target%2520of%2520the%2520bromodomain%2520inhibitor%2520JQ1%2520and%252C%2520combined%2520with%2520HLA%2520class%2520I%252C%2520a%2520promising%2520prognostic%2520biomarker%2520in%2520neuroblastoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2017%26volume%3D23%26spage%3D4462%26epage%3D4472%26doi%3D10.1158%2F1078-0432.ccr-16-2601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocik, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sala, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Czub, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stec, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siedlar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plewka, J.</span></span> <span> </span><span class="NLM_article-title">CA-170 - a potent small-molecule PD-L1 inhibitor or not?</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">2804</span>– <span class="NLM_lpage">2815</span>, <span class="refDoi"> DOI: 10.3390/molecules24152804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.3390%2Fmolecules24152804" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=2804-2815&author=B.+Musielakauthor=J.+Kocikauthor=L.+Skalniakauthor=K.+Magiera-Mularzauthor=D.+Salaauthor=M.+Czubauthor=M.+Stecauthor=M.+Siedlarauthor=T.+A.+Holakauthor=J.+Plewka&title=CA-170+-+a+potent+small-molecule+PD-L1+inhibitor+or+not%3F&doi=10.3390%2Fmolecules24152804"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3390%2Fmolecules24152804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules24152804%26sid%3Dliteratum%253Aachs%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKocik%26aufirst%3DJ.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSala%26aufirst%3DD.%26aulast%3DCzub%26aufirst%3DM.%26aulast%3DStec%26aufirst%3DM.%26aulast%3DSiedlar%26aufirst%3DM.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DPlewka%26aufirst%3DJ.%26atitle%3DCA-170%2520-%2520a%2520potent%2520small-molecule%2520PD-L1%2520inhibitor%2520or%2520not%253F%26jtitle%3DMolecules%26date%3D2019%26volume%3D24%26spage%3D2804%26epage%3D2815%26doi%3D10.3390%2Fmolecules24152804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magiera-Mularz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skalniak, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musielak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kholodovych, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holak, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">7250</span>– <span class="NLM_lpage">7263</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7250-7263&author=S.+Basuauthor=J.+Yangauthor=B.+Xuauthor=K.+Magiera-Mularzauthor=L.+Skalniakauthor=B.+Musielakauthor=V.+Kholodovychauthor=T.+A.+Holakauthor=L.+Hu&title=Design%2C+synthesis%2C+evaluation%2C+and+structural+studies+of+C2-symmetric+small+molecule+inhibitors+of+programmed+cell+death-1%2Fprogrammed+death-ligand+1+protein-protein+interaction&doi=10.1021%2Facs.jmedchem.9b00795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction</span></div><div class="casAuthors">Basu, Subhadwip; Yang, Jeffrey; Xu, Bin; Magiera-Mularz, Katarzyna; Skalniak, Lukasz; Musielak, Bogdan; Kholodovych, Vladyslav; Holak, Tad A.; Hu, Longqin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">7250-7263</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of C2-sym. inhibitors was designed and evaluated for inhibitory activity against the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein interaction (PPI) in a homogeneous time-resolved fluorescence (HTRF) assay and PD-1 signaling in cell-based coculture assays.  C2-sym. inhibitors 2a (LH1306) and 2b (LH1307) exhibited IC50 values of 25 and 3.0 nM, resp., in the HTRF assay.  While 2a was ∼3.8-fold more potent than previously reported inhibitor 1a, 2b could not be differentiated from 1b due to their high potency and the limit of our HTRF assay conditions.  In one cell-based coculture PD-1 signaling assay, 2a and 2b were 8.2- and 2.8-fold more potent in inhibiting PD-1 signaling than 1a and 1b, resp.  NMR and X-ray cocrystal structural studies provided more structural insights into the interaction between 2b and PD-L1; 2b binds to PD-L1 at the PD-1 binding site and induces the formation of a more sym. arranged PD-L1 homodimer than that previously reported for other inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqS9fdh7FbNLLVg90H21EOLACvtfcHk0li9ApTf7sU8PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlOhu7zJ&md5=0dae949116a4157a281802aea6d21b6c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00795%26sid%3Dliteratum%253Aachs%26aulast%3DBasu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DMagiera-Mularz%26aufirst%3DK.%26aulast%3DSkalniak%26aufirst%3DL.%26aulast%3DMusielak%26aufirst%3DB.%26aulast%3DKholodovych%26aufirst%3DV.%26aulast%3DHolak%26aufirst%3DT.%2BA.%26aulast%3DHu%26aufirst%3DL.%26atitle%3DDesign%252C%2520synthesis%252C%2520evaluation%252C%2520and%2520structural%2520studies%2520of%2520C2-symmetric%2520small%2520molecule%2520inhibitors%2520of%2520programmed%2520cell%2520death-1%252Fprogrammed%2520death-ligand%25201%2520protein-protein%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D7250%26epage%3D7263%26doi%3D10.1021%2Facs.jmedchem.9b00795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span> <span> </span><span class="NLM_article-title">Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4703</span>– <span class="NLM_lpage">4715</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvV2qurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4703-4715&author=M.+Qinauthor=Q.+Caoauthor=S.+Zhengauthor=Y.+Tianauthor=H.+Zhangauthor=J.+Xieauthor=H.+Xieauthor=Y.+Liuauthor=Y.+Zhaoauthor=P.+Gong&title=Discovery+of+%5B1%2C2%2C4%5DTriazolo%5B4%2C3-a%5Dpyridines+as+Potent+Inhibitors+Targeting+the+Programmed+Cell+Death-1%2FProgrammed+Cell+Death-Ligand+1+Interaction&doi=10.1021%2Facs.jmedchem.9b00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction</span></div><div class="casAuthors">Qin, Mingze; Cao, Qi; Zheng, Shuaishuai; Tian, Ye; Zhang, Haotian; Xie, Jun; Xie, Hongbo; Liu, Yajing; Zhao, Yanfang; Gong, Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4703-4715</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction using small-mol. inhibitors is an emerging immunotherapeutic approach.  A novel series of [1,2,4]triazolo[4,3-a]pyridines were designed and found to be potent inhibitors of the PD-1/PD-L1 interaction.  Among them, compd. I exhibited the most potent activity, as assessed by homogeneous time-resolved fluorescence assay, with an IC50 of 92.3 nM.  Furthermore, I dose-dependent elevated interferon-γ prodn. in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  The authors concluded that I is a promising lead compd. for the development of inhibitors of the PD-1/PD-L1 interaction.  In addn., the authors explored the structure-activity relationships of the newly synthesized [1,2,4]triazolo[4,3-a]pyridines and demonstrated that a ring fusion strategy can be employed for designing analogs of the Bristol-Myers Squibb chem. series.  These studies pave the way for future drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCgkEJ5SqGXLVg90H21EOLACvtfcHk0li9ApTf7sU8PQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvV2qurs%253D&md5=44d4ee689be577a86c16cc4da3edec71</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00312%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DP.%26atitle%3DDiscovery%2520of%2520%255B1%252C2%252C4%255DTriazolo%255B4%252C3-a%255Dpyridines%2520as%2520Potent%2520Inhibitors%2520Targeting%2520the%2520Programmed%2520Cell%2520Death-1%252FProgrammed%2520Cell%2520Death-Ligand%25201%2520Interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4703%26epage%3D4715%26doi%3D10.1021%2Facs.jmedchem.9b00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>199</i></span>,  <span class="NLM_fpage">112377</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112377</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1016%2Fj.ejmech.2020.112377" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=32388281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BB3cXptFGisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2020&pages=112377&author=B.+Chengauthor=Y.+Renauthor=H.+Caoauthor=J.+Chen&title=Discovery+of+novel+resorcinol+diphenyl+ether-based+PROTAC-like+molecules+as+dual+inhibitors+and+degraders+of+PD-L1&doi=10.1016%2Fj.ejmech.2020.112377"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1</span></div><div class="casAuthors">Cheng, Binbin; Ren, Yichang; Cao, Hao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112377</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Novel resorcinol di-Ph ether-based PROTACs (PROteolysis TArgeting Chimeras) were designed and evaluated for their inhibitory activity against the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) pathway and their ability to degrade PD-L1 protein.  Most of the compds. displayed excellent inhibitory activities against PD-1/PD-L1, as assessed by the homogeneous time-resolved fluorescence (HTRF) binding assay, with IC50 values ranging from 25 nM to 200 nM.  Among them, compd. P22 (I) is one of the best with an IC50 value of 39.2 nM.  In addn. to inhibiting PD-1/PD-L1 interaction, P22 also significantly restored the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  Furthermore, flow cytometry (FCM) and western-blot data demonstrated that P22 could moderately reduce the protein levels of PD-L1 in a lysosome-dependent manner, which may contribute to its immune effects.  Preliminary FCM and western-blot data suggest that it is possible to build PD-L1-targeting PROTAC-like mols. based on PD-1/PD-L1 small mol. inhibitors, though these compds. showed only modest degrdn. efficiencies.  Collectively, this work suggests that P22 may serve as a starting point for exploring the degrdn. of PD-L1 by PROTAC-like strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiG4nI2klh77Vg90H21EOLACvtfcHk0liR0fFmfA87cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXptFGisLk%253D&md5=ec722d2e118668f601c0f9648e6f893b</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112377&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112377%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520resorcinol%2520diphenyl%2520ether-based%2520PROTAC-like%2520molecules%2520as%2520dual%2520inhibitors%2520and%2520degraders%2520of%2520PD-L1%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D199%26spage%3D112377%26doi%3D10.1016%2Fj.ejmech.2020.112377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Qin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>186</i></span>,  <span class="NLM_fpage">111856</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111856</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1016%2Fj.ejmech.2019.111856" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=31734021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOmu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=186&publication_year=2020&pages=111856&author=M.+Qinauthor=Q.+Caoauthor=X.+Wuauthor=C.+Liuauthor=S.+Zhengauthor=H.+Xieauthor=Y.+Tianauthor=J.+Xieauthor=Y.+Zhaoauthor=Y.+Houauthor=X.+Zhangauthor=B.+Xuauthor=H.+Zhangauthor=X.+Wang&title=Discovery+of+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction+inhibitors+bearing+an+indoline+scaffold&doi=10.1016%2Fj.ejmech.2019.111856"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold</span></div><div class="casAuthors">Qin, Mingze; Cao, Qi; Wu, Xia; Liu, Chunyang; Zheng, Shuaishuai; Xie, Hongbo; Tian, Ye; Xie, Jun; Zhao, Yanfang; Hou, Yunlei; Zhang, Xian; Xu, Boxuan; Zhang, Haotian; Wang, Xiaobo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">186</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111856</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.  Here, a novel series of indoline-contg. compds. were developed, among which, A13 was identified as the most promising PD-1/PD-L1 pathway inhibitor.  At the biochem. level, A13 demonstrated strong inhibition of the PD-1/PD-L1 interaction, with an IC50 of 132.8 nM.  Notably, it exhibited outstanding immunoregulatory activity, and significantly elevated interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3 T cell co-culture model, without significant toxic effect.  Therefore, A13 could be employed as a suitable lead compd. for further design of non-peptide inhibitors targeting the PD-1/PD-L1 interaction.  In addn., the preliminary structure-activity relationships of these new indoline compds. were investigated in this study, providing valuable information for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7nYUI852jyLVg90H21EOLACvtfcHk0liR0fFmfA87cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOmu7zN&md5=b757929dd24437bb5af585e73a884a51</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111856&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111856%26sid%3Dliteratum%253Aachs%26aulast%3DQin%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DTian%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DHou%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%2520inhibitors%2520bearing%2520an%2520indoline%2520scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D186%26spage%3D111856%26doi%3D10.1016%2Fj.ejmech.2019.111856" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burr, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparbier, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beavis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, E. Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolzenburg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilan, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bloor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgens, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassik, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neeson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behren, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darcy, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voskoboinik, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trapani, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehner, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, M. A.</span></span> <span> </span><span class="NLM_article-title">CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>549</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1038/nature23643</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1038%2Fnature23643" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=28813417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlGktrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=549&publication_year=2017&pages=101-105&author=M.+L.+Burrauthor=C.+E.+Sparbierauthor=Y.-C.+Chanauthor=J.+C.+Williamsonauthor=K.+Woodsauthor=P.+A.+Beavisauthor=E.+Y.+N.+Lamauthor=M.+A.+Hendersonauthor=C.+C.+Bellauthor=S.+Stolzenburgauthor=O.+Gilanauthor=S.+Bloorauthor=T.+Nooriauthor=D.+W.+Morgensauthor=M.+C.+Bassikauthor=P.+J.+Neesonauthor=A.+Behrenauthor=P.+K.+Darcyauthor=S.-J.+Dawsonauthor=I.+Voskoboinikauthor=J.+A.+Trapaniauthor=J.+Cebonauthor=P.+J.+Lehnerauthor=M.+A.+Dawson&title=CMTM6+maintains+the+expression+of+PD-L1+and+regulates+anti-tumour+immunity&doi=10.1038%2Fnature23643"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity</span></div><div class="casAuthors">Burr, Marian L.; Sparbier, Christina E.; Chan, Yih-Chih; Williamson, James C.; Woods, Katherine; Beavis, Paul A.; Lam, Enid Y. N.; Henderson, Melissa A.; Bell, Charles C.; Stolzenburg, Sabine; Gilan, Omer; Bloor, Stuart; Noori, Tahereh; Morgens, David W.; Bassik, Michael C.; Neeson, Paul J.; Behren, Andreas; Darcy, Phillip K.; Dawson, Sarah-Jane; Voskoboinik, Ilia; Trapani, Joseph A.; Cebon, Jonathan; Lehner, Paul J.; Dawson, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">549</span>
        (<span class="NLM_cas:issue">7670</span>),
    <span class="NLM_cas:pages">101-105</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancer cells exploit the expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) to subvert T-cell-mediated immunosurveillance.  The success of therapies that disrupt PD-L1-mediated tumor tolerance has highlighted the need to understand the mol. regulation of PD-L1 expression.  Here we identify the uncharacterized protein CMTM6 as a crit. regulator of PD-L1 in a broad range of cancer cells, by using a genome-wide CRISPR-Cas9 screen.  CMTM6 is a ubiquitously expressed protein that binds PD-L1 and maintains its cell surface expression.  CMTM6 is not required for PD-L1 maturation but co-localizes with PD-L1 at the plasma membrane and in recycling endosomes, where it prevents PD-L1 from being targeted for lysosome-mediated degrdn.  Using a quant. approach to profile the entire plasma membrane proteome, we find that CMTM6 displays specificity for PD-L1.  Notably, CMTM6 depletion decreases PD-L1 without compromising cell surface expression of MHC class I.  CMTM6 depletion, via the redn. of PD-L1, significantly alleviates the suppression of tumor-specific T cell activity in vitro and in vivo.  These findings provide insights into the biol. of PD-L1 regulation, identify a previously unrecognized master regulator of this crit. immune checkpoint and highlight a potential therapeutic target to overcome immune evasion by tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOaE7qlrP04LVg90H21EOLACvtfcHk0liR0fFmfA87cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlGktrvK&md5=c37c58dcfa75b3057fe4e9635789281d</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fnature23643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature23643%26sid%3Dliteratum%253Aachs%26aulast%3DBurr%26aufirst%3DM.%2BL.%26aulast%3DSparbier%26aufirst%3DC.%2BE.%26aulast%3DChan%26aufirst%3DY.-C.%26aulast%3DWilliamson%26aufirst%3DJ.%2BC.%26aulast%3DWoods%26aufirst%3DK.%26aulast%3DBeavis%26aufirst%3DP.%2BA.%26aulast%3DLam%26aufirst%3DE.%2BY.%2BN.%26aulast%3DHenderson%26aufirst%3DM.%2BA.%26aulast%3DBell%26aufirst%3DC.%2BC.%26aulast%3DStolzenburg%26aufirst%3DS.%26aulast%3DGilan%26aufirst%3DO.%26aulast%3DBloor%26aufirst%3DS.%26aulast%3DNoori%26aufirst%3DT.%26aulast%3DMorgens%26aufirst%3DD.%2BW.%26aulast%3DBassik%26aufirst%3DM.%2BC.%26aulast%3DNeeson%26aufirst%3DP.%2BJ.%26aulast%3DBehren%26aufirst%3DA.%26aulast%3DDarcy%26aufirst%3DP.%2BK.%26aulast%3DDawson%26aufirst%3DS.-J.%26aulast%3DVoskoboinik%26aufirst%3DI.%26aulast%3DTrapani%26aufirst%3DJ.%2BA.%26aulast%3DCebon%26aufirst%3DJ.%26aulast%3DLehner%26aufirst%3DP.%2BJ.%26aulast%3DDawson%26aufirst%3DM.%2BA.%26atitle%3DCMTM6%2520maintains%2520the%2520expression%2520of%2520PD-L1%2520and%2520regulates%2520anti-tumour%2520immunity%26jtitle%3DNature%26date%3D2017%26volume%3D549%26spage%3D101%26epage%3D105%26doi%3D10.1038%2Fnature23643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span> <span> </span><span class="NLM_article-title">In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>629</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">381</span>, <span class="refDoi"> DOI: 10.1016/bs.mie.2019.05.051</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1016%2Fbs.mie.2019.05.051" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=31727249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisVyrt7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=629&publication_year=2019&pages=361-381&author=W.+Zhaiauthor=X.+Zhouauthor=J.+Duauthor=Y.+Gao&title=In+vitro+assay+for+the+development+of+small+molecule+inhibitors+targeting+PD-1%2FPD-L1&doi=10.1016%2Fbs.mie.2019.05.051"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1</span></div><div class="casAuthors">Zhai, Wenjie; Zhou, Xiuman; Du, Jiangfeng; Gao, Yanfeng</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">629</span>
        (<span class="NLM_cas:issue">Tumor Immunology and Immunotherapy: Molecular Methods</span>),
    <span class="NLM_cas:pages">361-381</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cancer immunotherapy has recently emerged as one of the hot research field since clin. successes achieved by antibody drugs of immune checkpoints, among which PD-1 and its ligand PD-L1 are the well established mols.  PD-1/PD-L1 pathway induces immune tolerance and immune evasion, esp. in tumor microenvironment, cancer cell is capable to escape the immune surveillance by up-regulating the expression level of PD-1 or PD-L1.  Blockade of PD-1/PD-L1 can unleash the anti-tumor activity, and the strategy shows great successes in the treatment of various cancer types in the late stage.  Beside antibody drugs, many other mols. such as peptides, high affinity PD(L)-1 mutants, chem. compds., and DNA aptamers are designed for inhibitors of PD-1/PD-L1 pathway.  Each modulators show their pros and cons based on their own physiochem. properties.  Here we introduced the methods for identifying low mol. wt. inhibitors of PD-1/PD-L1 and mainly discussed the cell-based blocking test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpciI296XaTR7Vg90H21EOLACvtfcHk0lgZGieBNC3QAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisVyrt7fM&md5=29aae0a76aecb165f5a5a28835f68845</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fbs.mie.2019.05.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fbs.mie.2019.05.051%26sid%3Dliteratum%253Aachs%26aulast%3DZhai%26aufirst%3DW.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DY.%26atitle%3DIn%2520vitro%2520assay%2520for%2520the%2520development%2520of%2520small%2520molecule%2520inhibitors%2520targeting%2520PD-1%252FPD-L1%26jtitle%3DMethods%2520Enzymol.%26date%3D2019%26volume%3D629%26spage%3D361%26epage%3D381%26doi%3D10.1016%2Fbs.mie.2019.05.051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of a chiral fluorinated azetidin-2-one as a tubulin polymerisation inhibitor with potent antitumour efficacy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">112323</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112323</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1016%2Fj.ejmech.2020.112323" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=32339854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVSqsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=2020&pages=112323&author=H.+Tangauthor=J.+Chengauthor=Y.+Liangauthor=Y.+Wang&title=Discovery+of+a+chiral+fluorinated+azetidin-2-one+as+a+tubulin+polymerisation+inhibitor+with+potent+antitumour+efficacy&doi=10.1016%2Fj.ejmech.2020.112323"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a chiral fluorinated azetidin-2-one as a tubulin polymerisation inhibitor with potent antitumour efficacy</span></div><div class="casAuthors">Tang, Hairong; Cheng, Jiayi; Liang, Yuru; Wang, Yang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112323</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Inhibition of tubulin polymn. with small mols. has been clin. validated as a promising therapy for multiple solid tumors.  Herein, a series of chiral azetidin-2-ones were asym. synthesized and biol. evaluated for antitumor activities.  Among them, a chiral fluorinated azetidin-2-one, I, was found to exhibit the most potent activities against five cancer cell lines, including a drug-resistant cell line, with IC50 values ranging from 1.0 to 3.6 nM.  Further mechanistic studies revealed that the compd. I worked by disrupting tubulin polymn., blocking the cell cycle in the G2/M phase, inducing cellular apoptosis, and suppressing angiogenesis.  Addnl., I exhibited higher human-microsomal metabolic stability and aq. soly. compared to those of combretastatin A-4.  Finally, I was also found to effectively inhibit tumor growth in a xenograft mice model with low toxicity and thus might be a promising lead for further clin. development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDnSPTbEHXcLVg90H21EOLACvtfcHk0lgZGieBNC3QAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVSqsb4%253D&md5=8e300a8fc60719d2f0732444ed959c4f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112323&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112323%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520a%2520chiral%2520fluorinated%2520azetidin-2-one%2520as%2520a%2520tubulin%2520polymerisation%2520inhibitor%2520with%2520potent%2520antitumour%2520efficacy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D197%26spage%3D112323%26doi%3D10.1016%2Fj.ejmech.2020.112323" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel resorcinol dibenzyl ethers targeting the programmed cell death-1/programmed cell death-ligand 1 interaction as potential anticancer agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">8338</span>– <span class="NLM_lpage">8358</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00574</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00574" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=8338-8358&author=B.+Chengauthor=Y.+Renauthor=X.+Niuauthor=W.+Wangauthor=S.+Wangauthor=Y.+Tuauthor=S.+Liuauthor=J.+Wangauthor=D.+Yangauthor=G.+Liaoauthor=J.+Chen&title=Discovery+of+novel+resorcinol+dibenzyl+ethers+targeting+the+programmed+cell+death-1%2Fprogrammed+cell+death-ligand+1+interaction+as+potential+anticancer+agents&doi=10.1021%2Facs.jmedchem.0c00574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents</span></div><div class="casAuthors">Cheng, Binbin; Ren, Yichang; Niu, Xiaoge; Wang, Wei; Wang, Shuanghu; Tu, Yingfeng; Liu, Shuwen; Wang, Jin; Yang, Deying; Liao, Guochao; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8338-8358</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel small mol. compds. based on various scaffolds including chalcone, flavonoid, and resorcinol dibenzyl ether were designed and tested for their inhibitory activity against the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) pathway.  Among them, compd. NP19(I) inhibited the human PD-1/PD-L1 interaction with IC50 values of 12.5 nM in homogeneous time-resolved fluorescence (HTRF) binding assays.  In addn., NP19 dose-dependently elevated IFN-γ prodn. in a coculture model of Hep3B/OS-8/hPD-L1 and CD3 T cells.  Furthermore, NP19 displayed significant in vivo antitumor efficacy in two different mouse models of cancer (a melanoma B16-F10 tumor model and an H22 hepatoma tumor model).  Moreover, H&E staining and flow cytometry data suggested that NP19 activated the immune microenvironment in the tumor, which may contribute to its antitumor effects.  This work shows NP19 is a promising lead compd. for further development as a new generation of small mol. inhibitors targeting the PD-1/PD-L1 pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruD5Zp9HM0jrVg90H21EOLACvtfcHk0lgZGieBNC3QAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2rsrfL&md5=a1f6b3b4c440a7152ed8194ad842370f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00574%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DB.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DD.%26aulast%3DLiao%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520novel%2520resorcinol%2520dibenzyl%2520ethers%2520targeting%2520the%2520programmed%2520cell%2520death-1%252Fprogrammed%2520cell%2520death-ligand%25201%2520interaction%2520as%2520potential%2520anticancer%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D8338%26epage%3D8358%26doi%3D10.1021%2Facs.jmedchem.0c00574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chow, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozga, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Servis, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frederick, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boland, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luster, A. D.</span></span> <span> </span><span class="NLM_article-title">Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">1498</span>– <span class="NLM_lpage">1512</span>, <span class="refDoi"> DOI: 10.1016/j.immuni.2019.04.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1016%2Fj.immuni.2019.04.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=31097342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlygt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=1498-1512&author=M.+T.+Chowauthor=A.+J.+Ozgaauthor=R.+L.+Servisauthor=D.+T.+Frederickauthor=J.+A.+Loauthor=D.+E.+Fisherauthor=G.+J.+Freemanauthor=G.+M.+Bolandauthor=A.+D.+Luster&title=Intratumoral+activity+of+the+CXCR3+chemokine+system+is+required+for+the+efficacy+of+anti-PD-1+therapy&doi=10.1016%2Fj.immuni.2019.04.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy</span></div><div class="casAuthors">Chow, Melvyn T.; Ozga, Aleksandra J.; Servis, Rachel L.; Frederick, Dennie T.; Lo, Jennifer A.; Fisher, David E.; Freeman, Gordon J.; Boland, Genevieve M.; Luster, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1498-1512.e5</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Despite compelling rates of durable clin. responses to programmed cell death-1 (PD-1) blockade, advances are needed to extend these benefits to resistant tumors.  We found that tumor-bearing mice deficient in the chemokine receptor CXCR3 responded poorly to anti-PD-1 treatment.  CXCR3 and its ligand CXCL9 were crit. for a productive CD8+ T cell response in tumor-bearing mice treated with anti-PD-1 but were not required for the infiltration of CD8+ T cells into tumors.  The anti-PD-1-induced anti-tumor response was facilitated by CXCL9 prodn.from intratumoral CD103+ dendritic cells, suggesting that CXCR3 facilitates dendritic cell-T cell interactions within the tumor microenvironment.  CXCR3 ligands in murine tumors and in plasma of melanoma patients were an indicator of clin. response to anti-PD-1, and their induction in non-responsive murine tumors promoted responsiveness to anti-PD-1.  Our data suggest that the CXCR3 chemokine system is a biomarker for sensitivity to PD-1 blockade and that augmenting the intratumoral function of this chemokine system could improve clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSw41CZG6jOLVg90H21EOLACvtfcHk0ljFAVLTASaYwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlygt7o%253D&md5=2244962249d55dcc7ad6c3dbdac81955</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.immuni.2019.04.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.immuni.2019.04.010%26sid%3Dliteratum%253Aachs%26aulast%3DChow%26aufirst%3DM.%2BT.%26aulast%3DOzga%26aufirst%3DA.%2BJ.%26aulast%3DServis%26aufirst%3DR.%2BL.%26aulast%3DFrederick%26aufirst%3DD.%2BT.%26aulast%3DLo%26aufirst%3DJ.%2BA.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DBoland%26aufirst%3DG.%2BM.%26aulast%3DLuster%26aufirst%3DA.%2BD.%26atitle%3DIntratumoral%2520activity%2520of%2520the%2520CXCR3%2520chemokine%2520system%2520is%2520required%2520for%2520the%2520efficacy%2520of%2520anti-PD-1%2520therapy%26jtitle%3DImmunity%26date%3D2019%26volume%3D50%26spage%3D1498%26epage%3D1512%26doi%3D10.1016%2Fj.immuni.2019.04.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juneja, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuire, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manguso, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFleur, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haining, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, A. H.</span></span> <span> </span><span class="NLM_article-title">PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity</span>. <i>J. Exp. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>214</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">904</span>, <span class="refDoi"> DOI: 10.1084/jem.20160801</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=10.1084%2Fjem.20160801" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=28302645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtV2ju7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=214&publication_year=2017&pages=895-904&author=V.+R.+Junejaauthor=K.+A.+McGuireauthor=R.+T.+Mangusoauthor=M.+W.+LaFleurauthor=N.+Collinsauthor=W.+N.+Hainingauthor=G.+J.+Freemanauthor=A.+H.+Sharpe&title=PD-L1+on+tumor+cells+is+sufficient+for+immune+evasion+in+immunogenic+tumors+and+inhibits+CD8+T+cell+cytotoxicity&doi=10.1084%2Fjem.20160801"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity</span></div><div class="casAuthors">Juneja, Vikram R.; McGuire, Kathleen A.; Manguso, Robert T.; LaFleur, Martin W.; Collins, Natalie; Haining, W. Nicholas; Freeman, Gordon J.; Sharpe, Arlene H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Experimental Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">214</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">895-904</span>CODEN:
                <span class="NLM_cas:coden">JEMEAV</span>;
        ISSN:<span class="NLM_cas:issn">1540-9538</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">It is unclear whether PD-L1 on tumor cells is sufficient for tumor immune evasion or simply correlates with an inflamed tumor microenvironment.  We used three mouse tumor models sensitive to PD-1 blockade to evaluate the significance of PD-L1 on tumor vs. nontumor cells.  PD-L1 on nontumor cells is crit. for inhibiting antitumor immunity in B16 melanoma and a genetically engineered melanoma.  In contrast, PD-L1 on MC38 colorectal adenocarcinoma cells is sufficient to suppress antitumor immunity, as deletion of PD-L1 on highly immunogenic MC38 tumor cells allows effective antitumor immunity.  MC38-derived PD-L1 potently inhibited CD8+ T cell cytotoxicity.  Wild-type MC38 cells outcompeted PD-L1-deleted MC38 cells in vivo, demonstrating tumor PD-L1 confers a selective advantage.  Thus, both tumor- and host-derived PD-L1 can play crit. roles in immunosuppression.  Differences in tumor immunogenicity appear to underlie their relative importance.  Our findings establish reduced cytotoxicity as a key mechanism by which tumor PD-L1 suppresses antitumor immunity and demonstrate that tumor PD-L1 is not just a marker of suppressed antitumor immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOvfjGoOhPg7Vg90H21EOLACvtfcHk0ljFAVLTASaYwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtV2ju7nJ&md5=95ceac8e66dd13f327bfc0eb3dab42c1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1084%2Fjem.20160801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1084%252Fjem.20160801%26sid%3Dliteratum%253Aachs%26aulast%3DJuneja%26aufirst%3DV.%2BR.%26aulast%3DMcGuire%26aufirst%3DK.%2BA.%26aulast%3DManguso%26aufirst%3DR.%2BT.%26aulast%3DLaFleur%26aufirst%3DM.%2BW.%26aulast%3DCollins%26aufirst%3DN.%26aulast%3DHaining%26aufirst%3DW.%2BN.%26aulast%3DFreeman%26aufirst%3DG.%2BJ.%26aulast%3DSharpe%26aufirst%3DA.%2BH.%26atitle%3DPD-L1%2520on%2520tumor%2520cells%2520is%2520sufficient%2520for%2520immune%2520evasion%2520in%2520immunogenic%2520tumors%2520and%2520inhibits%2520CD8%2520T%2520cell%2520cytotoxicity%26jtitle%3DJ.%2520Exp.%2520Med.%26date%3D2017%26volume%3D214%26spage%3D895%26epage%3D904%26doi%3D10.1084%2Fjem.20160801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIU','PDB','5NIU'); return false;">PDB: 5NIU</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i64"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01684">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_73185"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01684?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01684</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H NMR, <sup>13</sup>C NMR, HRMS, and HPLC spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01684/suppl_file/jm0c01684_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01684/suppl_file/jm0c01684_si_002.csv">CSV</a>)</p></li><li><p class="inline"><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5NIU">5NIU</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01684/suppl_file/jm0c01684_si_003.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01684/suppl_file/jm0c01684_si_001.pdf">jm0c01684_si_001.pdf (3.37 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01684/suppl_file/jm0c01684_si_002.csv">jm0c01684_si_002.csv (2.48 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01684/suppl_file/jm0c01684_si_003.pdb">jm0c01684_si_003.pdb (399.78 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01684&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-24%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01684%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01684" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679981491aed22d8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
